| Medicines/Item |
Section |
Status |
Link Name / Link URL |
| Holmium-166 microsphere |
19 |
Formulary
|
TA985: Selective internal radiation therapy with QuiremSpheres for treating unresectable advanced hepatocellular carcinoma |
| Abaloparatide |
06.06.01 |
Formulary
|
NICE TA991 : Abaloparatide for treating osteoporosis after menopause |
| Abatacept |
10.01.03 |
Formulary
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis |
| Abatacept |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Abatacept |
10.01.03 |
Formulary
|
NICE TA715: Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed |
| Abemaciclib |
08.03.04.01 |
Formulary
|
NICE TA 563: Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer |
| Abemaciclib |
08.03.04.01 |
Formulary
|
NICE TA810: Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence |
| Abemaciclib |
08.03.04.01 |
Formulary
|
NICE TA725: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy |
| Abiraterone |
08.03.04.02 |
Formulary
|
NICE TA259: Abiraterone for castration resistant prostate cancer |
| Abiraterone |
08.03.04.02 |
Formulary
|
NICE TA387:Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated |
| Abrocitinib |
13.05.03 |
Formulary
|
NICE TA814: Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis |
| Acalabrutinib |
08.01.05 |
Formulary
|
NICE TA689: Acalabrutinib for treating chronic lymphocytic leukaemia |
| Adalimumab |
13.05.03 |
Formulary
|
NICE TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa |
| Adalimumab |
13.05.03 |
Formulary
|
NICE TA146 Adalimumab for the treatment of adults with psoriasis |
| Adalimumab |
13.05.03 |
Formulary
|
NICE TA455 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
| Adalimumab |
01.05.03 |
Formulary
|
NICE TA187: Crohn’s disease - infliximab and adalimumab |
| Adalimumab |
01.05.03 |
Formulary
|
NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis |
| Adalimumab |
10.01.03 |
Formulary
|
NICE TA715: Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed |
| Adalimumab |
10.01.03 |
Formulary
|
NICE TA199: Psoriatic arthritis |
| Adalimumab |
10.01.03 |
Formulary
|
NICE TA195: Rheumatoid arthritis - after failure of a TNF inhibitor |
| Adalimumab |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Adalimumab |
10.01.03 |
Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Adalimumab |
10.01.03 |
Formulary
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis |
| Adalimumab |
11.04.02 |
Formulary
|
NICE TA460 Adalimumab and dexamethasone for treating non-infectious uveitis |
| Adefovir Dipivoxil |
05.03.03.01 |
Formulary
|
NICE TA96: Hep B - adefovir dipivoxil and pegylated interferon alpha-2a |
| Adefovir Dipivoxil |
05.03.03.01 |
Formulary
|
NICE CG165: Hepatitis B (chronic) - incorporates TA96 |
| Afamelanotide |
13.14.07 |
Non Formulary
|
NICE HST27: Afamelanotide for treating erythropoietic protoporphyria |
| Afatinib |
08.01.05 |
Formulary
|
NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer |
| Aflibercept |
08.01.05 |
Formulary
|
NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy |
| Aflibercept |
11.08.02 |
Formulary
|
NICE TA 346 Aflibercept for treating diabetic macular oedema |
| Aflibercept |
11.08.02 |
Formulary
|
NICE TA 305 Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion |
| Aflibercept |
11.08.02 |
Formulary
|
NICE TA 294 Aflibercept solution for injection for treating wet age‑related macular degeneration |
| Aflibercept |
11.08.02 |
Formulary
|
NICE TA 486: Aflibercept for treating choroidal neovascularisation |
| Aflibercept |
11.08.02 |
Formulary
|
NICE TA 409: Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion |
| Alectinib |
08.01.05 |
Formulary
|
NICE TA1014: Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer |
| Alectinib |
08.01.05 |
Formulary
|
NICE TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer |
| Alemtuzumab |
08.02.03 |
Non Formulary
|
NICE TA312: Alemtuzumab for relapsing‑remitting multiple sclerosis |
| Alemtuzumab |
08.02.03 |
Formulary
|
NICE TA312: Alemtuzumab for relapsing‑remitting multiple sclerosis |
| Alemtuzumab |
08.02.03 |
Formulary
|
NICE TA312: Alemtuzumab for relapsing‑remitting multiple sclerosis |
| Alendronic Acid |
06.06.02 |
Formulary
|
NICE TA464 Bisphosphonates for treating osteoporosis |
| Alirocumab |
02.12 |
Non Formulary
|
NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia |
| Alirocumab |
02.12 |
Formulary
|
NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia |
| Alitretinoin |
13.05.01 |
Formulary
|
NICE TA177: Alitretinoin for the treatment of severe chronic hand eczema |
| Alpelisib |
08.03.04.01 |
Formulary
|
NICE TA816: Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer |
| Alteplase |
02.10.02 |
Formulary
|
NICE TA264: Ischaemic stroke (acute) - alteplase |
| Alteplase |
02.10.02 |
Formulary
|
NICE NG128: Stroke and transient ischaemic attack in over 16s: diagnosis and initial management |
| Anakinra |
10.01.03 |
Formulary
|
NICE TA685: Anakinra for treating Still’s disease |
| Anastrozole |
08.03.04.01 |
Formulary
|
NICE CG164: Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer |
| Andexanet alfa |
02.08.02 |
Formulary
|
NICE TA697: Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban |
| Anti-D (Rh0) Immunoglobulin |
14.05.03 |
Non Formulary
|
NICE TA156: Anti-D in pregnant women |
| Apalutamide |
08.03.04.02 |
Formulary
|
NICE TA740: Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer |
| Apalutamide |
08.03.04.02 |
Formulary
|
NICE TA741: Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer |
| Apixaban |
02.08.02 |
Formulary
|
NICE TA245: Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults |
| Apixaban |
02.08.02 |
Formulary
|
NICE TA341: Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism |
| Apixaban |
02.08.02 |
Formulary
|
NICE TA275: Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation |
| Apremilast |
10.01.03 |
Formulary
|
NICE TA433: Apremilast for treating active psoriatic arthritis |
| Apremilast |
13.05.03 |
Formulary
|
NICE TA419: Apremilast for treating moderate to severe plaque psoriasis |
| Aripiprazole |
04.02.02 |
Formulary
|
NICE CG178: Psychosis and schizophrenia in adults: prevention and management |
| Aripiprazole |
04.02.01 |
Formulary
|
NICE TA213: Aripiprazole for the treatment of schizophrenia in people aged 15 -17 years |
| Aripiprazole |
04.02.01 |
Formulary
|
NICE TA292: Bipolar disorder (children) - aripiprazole |
| Arsenic Trioxide |
08.01.05 |
Formulary
|
NICE TA526: Arsenic trioxide for treating acute promyelocytic leukaemia |
| Asciminib |
08.01.05 |
Formulary
|
NICE TA813: Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors |
| Asfotase alfa |
09.08.01 |
Formulary
|
NICE HST23: Asfotase alfa for treating paediatric-onset hypophosphatasia |
| Ataluren |
10.02.01 |
Formulary
|
NICE HST22: Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene |
| Atezolizumab |
08.01.05 |
Formulary
|
NICE TA638: Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer |
| Atezolizumab |
08.01.05 |
Formulary
|
NICE TA639: Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer |
| Atezolizumab |
08.01.05 |
Formulary
|
NICE TA739: Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable |
| Atezolizumab |
08.01.05 |
Formulary
|
NICE TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy |
| Atezolizumab |
08.01.05 |
Formulary
|
NICE TA520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy |
| Atezolizumab |
08.01.05 |
Formulary
|
NICE TA705: Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer |
| Atezolizumab |
08.01.05 |
Formulary
|
NICE TA666: Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma |
| Atezolizumab |
08.01.05 |
Formulary
|
NICE TA1071: Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer |
| Atezolizumab |
08.01.05 |
Formulary
|
NICE TA584: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer |
| Atezolizumab |
08.01.05 |
Non Formulary
|
NICE TA1047:Atezolizumab for untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is unsuitable (terminated appraisal) |
| Atidarsagene autotemcel |
19 |
Formulary
|
NICE HST18: Atidarsagene autotemcel for treating metachromatic leukodystrophy |
| Atogepant |
04.07.04.02 |
Formulary
|
NICE TA973: Atogepant for preventing migraine |
| Autologous CD34+ enriched cell fraction |
08.01.05 |
Formulary
|
NICE HST7: Strimvelis for treating adenosine deaminase deficiency–severe combined immunodeficiency |
| Avalglucosidase alfa |
09.08.01 |
Formulary
|
NICE TA821: Avalglucosidase alfa for treating Pompe disease |
| Avapritinib |
08.01.05 |
Formulary
|
NICE TA1012: Avapritinib for treating advanced systemic mastocytosis |
| Avatrombopag |
09.01.04 |
Formulary
|
NICE TA626: Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure |
| Avatrombopag |
09.01.04 |
Formulary
|
NICE TA853: Avatrombopag for treating primary chronic immune thrombocytopenia |
| Avelumab |
08.02.03 |
Formulary
|
NICE TA788: Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy |
| Avelumab |
08.02.03 |
Formulary
|
NICE TA645: Avelumab with axitinib for untreated advanced renal cell carcinoma |
| Avelumab |
08.02.03 |
Formulary
|
NICE TA691: Avelumab for treating metastatic Merkel cell carcinoma |
| Axicabtagene ciloleucel |
08.01.05 |
Formulary
|
NICE TA895: Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy |
| Axicabtagene ciloleucel |
08.01.05 |
Formulary
|
NICE TA872: Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies |
| Axitinib |
08.01.05 |
Formulary
|
NICE TA333: Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment |
| Axitinib |
08.01.05 |
Formulary
|
NICE TA645: Avelumab with axitinib for untreated advanced renal cell carcinoma |
| Azacitidine |
08.01.03 |
Formulary
|
NICE TA218: Azacitidine for myelodysplastic syndromes |
| Azacitidine |
08.01.03 |
Formulary
|
NICE TA399: Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts |
| Azacitidine |
08.01.03 |
Formulary
|
NICE TA827: Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy |
| Baricitinib |
10.01.03 |
Formulary
|
NICE TA681: Baricitinib for treating moderate to severe atopic dermatitis |
| Baricitinib |
10.01.03 |
Formulary
|
NICE TA466: Baricitinib for moderate to severe rheumatoid arthritis |
| Baricitinib |
13.05.03 |
Formulary
|
NICE TA681: Baricitinib for treating moderate to severe atopic dermatitis |
| Baricitinib |
10.01.03 |
Non Formulary
|
NICE TA982: Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal) |
| Baricitinib |
13.05.03 |
Non Formulary
|
NICE TA926: Baricitinib for treating severe alopecia areata |
| Basiliximab |
08.02.02 |
Formulary
|
NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people |
| Basiliximab |
08.02.02 |
Formulary
|
NICE TA481: Immunosuppressive therapy for kidney transplant in adults |
| Bee and Wasp Allergen Extracts |
03.04.02 |
Formulary
|
NICE TA246: Pharmalgen for the treatment of bee and wasp venom allergy |
| Belimumab |
10.01.03 |
Formulary
|
NICE TA752: Belimumab for treating active autoantibody-positive systemic lupus erythematosus |
| Belimumab |
10.01 |
Formulary
|
NICE TA397: Belimumab for treating active autoantibody-positive systemic lupus erythematosus |
| Belumosudil |
08.02.02 |
Formulary
|
NICE TA949: Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over |
| Belzutifan |
08.01.05 |
Formulary
|
NICE TA1011: Belzutifan for treating tumours associated with von Hippel-Lindau disease |
| Bempedoic acid |
02.12 |
Formulary
|
NICE TA694 - Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia |
| Bempedoic acid with ezetimibe |
02.12 |
Formulary
|
NICE TA694 - Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia |
| Bendamustine |
08.01.01 |
Formulary
|
NICE TA216: Bendamustine for CLL |
| Benralizumab |
03.04.02 |
Formulary
|
NICE TA565: Benralizumab for treating severe eosinophilic asthma |
| Benralizumab |
03.04.02 |
Formulary
|
NICE TA1096: Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis |
| Berotralstat |
03.04.03 |
Formulary
|
NICE TA738: Berotralstat for preventing recurrent attacks of hereditary angioedema |
| Bevacizumab |
08.01.05 |
Formulary
|
NICE TA285: Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab |
| Bevacizumab |
08.01.05 |
Formulary
|
NICE TA284:Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer |
| Bevacizumab |
08.01.05 |
Formulary
|
NICE TA353: Bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal) |
| Bevacizumab gamma |
11.08.02 |
Formulary
|
NICE TA1022: Bevacizumab gamma for treating wet age-related macular degeneration |
| Bimekizumab |
13.05.03 |
Formulary
|
NICE TA723: Bimekizumab for treating moderate to severe plaque psoriasis |
| Bimekizumab |
10.01.03 |
Formulary
|
NICE TA918: Bimekizumab for treating axial spondyloarthritis |
| Bimekizumab |
10.01.03 |
Formulary
|
NICE TA916: Bimekizumab for treating active psoriatic arthritis |
| Birch bark extract |
13.14.07 |
Formulary
|
NICE HST28: Birch bark extract for treating epidermolysis bullosa |
| Bivalirudin |
02.08.01 |
Formulary
|
NICE NG185: Acute coronary syndromes |
| Blinatumomab |
08.02 |
Formulary
|
NICE TA450 Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia |
| Blinatumomab |
08.02 |
Formulary
|
NICE TA589: Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity |
| Blinatumomab |
08.02 |
Formulary
|
NICE TA1049: Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemia |
| Bortezomib |
08.01.05 |
Formulary
|
NICE TA370: Bortezomib for previously untreated mantle cell lymphoma |
| Bortezomib |
08.01.05 |
Formulary
|
NICE TA129: Bortezomib monotherapy for relapsed multiple myeloma |
| Bortezomib |
08.01.05 |
Formulary
|
NICE TA311: Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation |
| Bortezomib |
08.01.05 |
Formulary
|
NICE TA228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma |
| Bosutinib |
08.01.05 |
Formulary
|
NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia |
| Botulinum Toxin Type A |
04.07.04.02 |
Formulary
|
NICE TA260: Botulinum toxin type A for the prevention of headaches in adults with chronic migraine |
| Botulinum Toxin Type A injection |
04.09.03 |
Formulary
|
NICE TA605: Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea |
| Brentuximab vedotin |
08.01.05 |
Formulary
|
NICE TA1059: Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma |
| Brentuximab vedotin |
08.01.05 |
Formulary
|
NICE TA641: Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma |
| Brentuximab vedotin |
08.01.05 |
Formulary
|
NICE TA478 Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma |
| Brentuximab vedotin |
08.01.05 |
Formulary
|
NICE TA577: Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma |
| Brentuximab vedotin |
08.01.05 |
Formulary
|
NICE TA524 Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma |
| Brexucabtagene autoleucel |
08.01.05 |
Formulary
|
NICE TA893: Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over |
| Brigatinib |
08.01.05 |
Formulary
|
NICE TA670: Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor |
| Brigatinib |
08.01.05 |
Formulary
|
NICE TA571: Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib |
| Brodalumab |
13.05.03 |
Formulary
|
NICE TA511: Brodalumab for treating moderate to severe plaque psoriasis |
| Brolucizumab |
11.08.02 |
Formulary
|
NICE TA820: Brolucizumab for treating diabetic macular oedema |
| Brolucizumab |
11.08.02 |
Formulary
|
NICE TA672: Brolucizumab for treating wet age-related macular degeneration |
| Budesonide |
01.05.02 |
Formulary
|
NICE TA937: Targeted-release budesonide for treating primary IgA nephropathy |
| Budesonide |
01.05.02 |
Formulary
|
NICE TA708 - Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis |
| Bulevirtide |
05.03.03.02 |
Formulary
|
NICE TA896: Bulevirtide for treating chronic hepatitis D |
| Burosumab |
06.06.02 |
Formulary
|
NICE HST 8: Burosumab for treating X-linked hypophosphataemia in children and young people |
| Burosumab |
06.06.02 |
Formulary
|
NICE TA993 : Burosumab for treating X-linked hypophosphataemia in adults |
| Cabazitaxel |
08.01.05 |
Formulary
|
NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel |
| Cabotegravir |
05.03.01 |
Formulary
|
NICE TA757: Cabotegravir with rilpivirine for treating HIV-1 |
| Cabozantinib |
08.01.05 |
Formulary
|
NICE TA849: Cabozantinib for previously treated advanced hepatocellular carcinoma |
| Cabozantinib |
08.01.05 |
Formulary
|
NICE TA516: Cabozantinib for treating medullary thyroid cancer |
| Cabozantinib |
08.01.05 |
Formulary
|
NICE TA964: Cabozantinib with nivolumab for untreated advanced renal cell carcinoma |
| Cabozantinib |
08.01.05 |
Formulary
|
NICE TA463 Cabozantinib for previously treated advanced renal cell carcinoma |
| Cabozantinib |
08.01.05 |
Formulary
|
NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma |
| Canagliflozin |
06.01.02.03 |
Formulary
|
NICE TA315: Canagliflozin for type 2 diabetes |
| Canagliflozin |
06.01.02.03 |
Formulary
|
NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes |
| Cannabidiol |
04.06 |
Formulary
|
NICE TA614: Cannabidiol with clobazam for treating seizures associated with Dravet syndrome |
| Cannabidiol |
04.06 |
Formulary
|
NICE TA615: Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome |
| Cannabidiol |
04.08.01 |
Formulary
|
NICE TA873: Cannabidiol for treating seizures caused by tuberous sclerosis complex |
| Cannabidiol |
04.08.01 |
Formulary
|
NICE TA614: Cannabidiol with clobazam for treating seizures associated with Dravet syndrome |
| Cannabidiol |
04.08.01 |
Formulary
|
NICE TA615: Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome |
| Cannabis extract |
10.02.02 |
Formulary
|
NICE NG144: Cannabis-based medicinal products |
| Capecitabine |
08.01.03 |
Formulary
|
NICE TA191: Capecitabine for the treatment of advanced gastric cancer |
| Capecitabine |
08.01.03 |
Formulary
|
NICE TA61: Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer |
| Capecitabine |
08.01.03 |
Formulary
|
NICE TA100: Capecitabine and oxaliplatin in the adjuvant treatment of stage 3 (Dukes’ C) colon cancer |
| Capivasertib |
08.01.05 |
Formulary
|
NICE TA1063: Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment |
| Caplacizumab |
09.01.04 |
Formulary
|
NICE TA667: Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura |
| Capsaicin |
10.03.02 |
Formulary
|
NICE NG226 - Osteoarthritis in over 16s: diagnosis and management |
| Carfilzomib |
08.01.05 |
Formulary
|
NICE TA695: Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma |
| Carfilzomib |
08.01.05 |
Formulary
|
NICE TA657: Carfilzomib for previously treated multiple myeloma (COVID-19) |
| Carmustine |
08.01.01 |
Non Formulary
|
NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide |
| Carmustine |
08.01.01 |
Formulary
|
NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide |
| Casirivimab with Imdevimab |
05.03.06 |
Non Formulary
|
NICE TA878: Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 |
| Cemiplimab |
08.01.05 |
Formulary
|
NICE TA802: Cemiplimab for treating advanced cutaneous squamous cell carcinoma |
| Cenobamate |
04.08.01 |
Formulary
|
NICE TA753: Cenobamate for treating focal onset seizures in epilepsy |
| Ceritinib |
08.01.05 |
Formulary
|
NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer |
| Ceritinib |
08.01.05 |
Formulary
|
NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer |
| Cerliponase alfa |
06.07 |
Formulary
|
NICE HST12 : Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 |
| Certolizumab Pegol |
10.01.03 |
Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Certolizumab Pegol |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Certolizumab Pegol |
10.01.03 |
Formulary
|
NICE TA 415 - Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor |
| Certolizumab Pegol |
10.01.03 |
Formulary
|
NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs |
| Certolizumab Pegol |
10.01.03 |
Formulary
|
NICE TA574: Certolizumab pegol for treating moderate to severe plaque psoriasis |
| Certolizumab pegol |
13.05.03 |
Formulary
|
NICE TA574: Certolizumab pegol for treating moderate to severe plaque psoriasis |
| Cetuximab |
08.01.05 |
Formulary
|
NICE TA145: Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck |
| Cetuximab |
08.01.05 |
Formulary
|
NICE TA242: Cetuximab for the treatment of metastatic colorectal cancer after first-line chemotherapy: monotherapy or combination chemotherapy |
| Cetuximab |
08.01.05 |
Formulary
|
NICE TA439 Cetuximab and panitumumab for previously untreated metastatic colorectal cancer |
| Cetuximab |
08.01.05 |
Formulary
|
NICE TA473 Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (oral cavity) |
| Chlormethine hydrochloride |
08.01.01 |
Formulary
|
NICE TA720: Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma |
| Ciclosporin |
11.08.02.04 |
Non Formulary
|
NICE TA369 - Ciclosporin for treating eye disease that has not improved despite treatment with artificial tears |
| Ciclosporin 0.09% (0.9mg/1ml) Eye Drops |
11.04.02 |
Formulary
|
NICE TA369: Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears |
| Ciclosporin 0.1% (1mg/1ml) Eye Drops |
11.04.02 |
Formulary
|
NICE TA369: Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears |
| Cinacalcet |
09.05.01.02 |
Formulary
|
NICE TA117: Hyperparathyroidism - cinacalcet |
| Cipaglucosidase alfa (CIPA) |
09.08.01 |
Formulary
|
NICE TA912: Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease |
| Cladribine |
08.01.03 |
Formulary
|
NICE TA1053: Cladribine for treating active relapsing forms of multiple sclerosis |
| Cladribine |
08.01.03 |
Formulary
|
NICE TA616: Cladribine for treating relapsing–remitting multiple sclerosis |
| Clopidogrel |
02.09 |
Formulary
|
NICE TA210: Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events |
| Colistimethate |
05.01.07 |
Formulary
|
TA276:Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis |
| Colistimethate inhaler |
05.01.07 |
Non Formulary
|
NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin |
| Collagenase |
10.03.01 |
Formulary
|
NICE TA459 Collagenase clostridium histolyticum for treating Dupuytren’s contracture |
| Crizanlizumab |
08.01.05 |
Formulary
|
NICE TA743: Crizanlizumab for preventing sickle cell crises in sickle cell disease |
| Crizotinib |
08.01.05 |
Formulary
|
NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer |
| Crizotinib |
08.01.05 |
Formulary
|
NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer |
| Crizotinib |
08.01.05 |
Formulary
|
NICE TA1021: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer |
| Crovalimab |
09.01.03 |
Formulary
|
NICE TA1019: Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over |
| Cyanocobalamin 1mg tablets |
09.01.02 |
Formulary
|
NICE NG239: Vitamin B12 deficiency in over 16s: diagnosis and management |
| Dabigatran |
02.08.02 |
Formulary
|
NICE TA327: Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism |
| Dabigatran |
02.08.02 |
Formulary
|
NICE TA157: Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults |
| Dabigatran |
02.08.02 |
Formulary
|
NICE TA249: Dabigatran for Stroke prevention in AF |
| Dabrafenib |
08.01.05 |
Formulary
|
NICE TA977: Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over |
| Dabrafenib |
08.01.05 |
Formulary
|
NICE TA321: Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma |
| Dabrafenib |
08.01.05 |
Formulary
|
NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma |
| Dabrafenib |
08.01.05 |
Formulary
|
NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma |
| Dabrafenib |
08.01.05 |
Formulary
|
NICE TA898: Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer |
| Dacomitinib |
08.01.05 |
Formulary
|
NICE TA595: Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer |
| Danicopan |
09.01.03 |
Formulary
|
NICE TA1010: Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria |
| Dapagliflozin |
02.15 |
Formulary
|
NICE TA902: Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction |
| Dapagliflozin |
02.15 |
Formulary
|
NICE TA679: Dapagliflozin for treating chronic heart failure with reduced ejection fraction |
| Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes |
| Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA1075: Dapagliflozin for treating chronic kidney disease |
| Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes |
| Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA418: Dapagliflozin in triple therapy for treating type 2 diabetes |
| Daratumumab |
08.01.05 |
Formulary
|
NICE TA783: Daratumumab monotherapy for treating relapsed and refractory multiple myeloma |
| Daratumumab |
08.01.05 |
Formulary
|
NICE TA763: Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable |
| Daratumumab |
08.01.05 |
Formulary
|
NICE TA897: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma |
| Daratumumab |
08.01.05 |
Formulary
|
NICE TA917: Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable |
| Daratumumab |
08.01.05 |
Formulary
|
NICE TA959: Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis |
| Darbepoetin Alfa |
09.01.03 |
Formulary
|
NICE NG203: Chronic kidney disease: assessment and management |
| Darbepoetin Alfa |
09.01.03 |
Formulary
|
NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy |
| Daridorexant |
04.01.01 |
Formulary
|
NICE TA922: Daridorexant for treating long-term insomnia |
| Darolutamide |
08.03.04.02 |
Formulary
|
NICE TA660: Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer |
| Darolutamide |
08.03.04.02 |
Formulary
|
NICE TA903: Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer |
| Dasabuvir |
05.03.03.02 |
Non Formulary
|
NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C |
| Dasatinib |
08.01.05 |
Formulary
|
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia |
| Dasatinib |
08.01.05 |
Formulary
|
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia |
| Daunorubicin/cytarabine |
08.01.03 |
Formulary
|
NICE TA 552: Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia |
| Decitabine |
08.01.03 |
Non Formulary
|
NICE TA270: Leukaemia (acute myeloid ) - decitabine (terminated appraisal) |
| Degarelix |
08.03.04.02 |
Formulary
|
NICE TA404: Degarelix for treating advanced hormone-dependent prostate cancer |
| Denosumab |
06.06.02 |
Formulary
|
NICE TA204: Osteoporotic fractures - denosumab |
| Denosumab |
06.06.02 |
Formulary
|
NICE TA265: Bone metastases from solid tumours - denosumab: guidance |
| Deucravacitinib |
13.05.03 |
Formulary
|
NICE TA907: Deucravacitinib for treating moderate to severe plaque psoriasis |
| Dexamethasone 700 microgram intravitreal implant |
11.04.01 |
Formulary
|
NICE TA460 Adalimumab and dexamethasone for treating non-infectious uveitis |
| Dexamethasone 700 microgram intravitreal implant |
11.04.01 |
Formulary
|
NICE TA229 Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion |
| Dexamethasone 700 microgram intravitreal implant |
11.04.01 |
Formulary
|
NICE TA824: Dexamethasone intravitreal implant for treating diabetic macular oedema |
| Dimethyl fumarate |
13.05.03 |
Formulary
|
NICE TA475 Dimethyl fumarate for treating moderate to severe plaque psoriasis |
| Dimethyl fumarate |
08.02.04 |
Formulary
|
NICE TA320: Dimethyl fumarate for multiple sclerosis |
| Dinutuximab beta |
08.01.05 |
Formulary
|
NICE TA 538: Dinutuximab beta for treating neuroblastoma |
| Dipyridamole |
02.09 |
Formulary
|
NICE TA210: Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events |
| Diroximel fumarate |
08.02.04 |
Formulary
|
NICE TA794: Diroximel fumarate for treating relapsing–remitting multiple sclerosis |
| Docetaxel |
08.01.05 |
Formulary
|
NICE NG101: Early and locally advanced breast cancer: diagnosis and management |
| Docetaxel |
08.01.05 |
Formulary
|
NICE TA101: Docetaxel for the treatment of hormone-refractory metastatic prostate cancer |
| Donepezil |
04.11 |
Formulary
|
NICE TA217: Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease |
| Dostarlimab |
08.01.05 |
Formulary
|
NICE TA779: Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency |
| Dostarlimab |
08.01.05 |
Formulary
|
NICE TA1064: Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency |
| Doxorubicin |
08.01.02 |
Formulary
|
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
| Dronedarone |
02.03.02 |
Formulary
|
NICE TA197 (Atrial fibrillation - dronedarone) |
| Dulaglutide |
06.01.02.03 |
Formulary
|
NICE NG18: Diabetes (type 1 and type 2) in children and young people: diagnosis and management |
| Dupilumab |
13.05.03 |
Formulary
|
NICE TA534: Dupilumab for treating moderate to severe atopic dermatitis |
| Dupilumab |
03.04.02 |
Formulary
|
NICE TA751: Dupilumab for treating severe asthma with type 2 inflammation |
| Dupilumab |
01.05.03 |
Non Formulary
|
NICE TA938: Dupilumab for treating eosinophilic oesophagitis in people 12 years and over (terminated appraisal) |
| Dupilumab |
13.05.03 |
Non Formulary
|
NICE TA955: Dupilumab for treating moderate to severe prurigo nodularis |
| Durvalumab |
08.01.05 |
Formulary
|
NICE TA798: Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation |
| Durvalumab |
08.01.05 |
Formulary
|
NICE TA1041: Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer |
| Durvalumab |
08.01.05 |
Formulary
|
NICE TA1030: Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer |
| Durvalumab |
08.01.05 |
Formulary
|
NICE TA1064: Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency |
| Durvalumab |
08.01.05 |
Formulary
|
NICE TA1090: Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma |
| Durvalumab |
08.01.05 |
Formulary
|
NICE TA944: Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer |
| Eculizumab |
09.01.03 |
Formulary
|
NICE HST 1 - Eculizumab for treating atypical haemolytic uraemic syndrome |
| Eculizumab |
09.01.03 |
Formulary
|
NICE TA636: Eculizumab for treating refractory myasthenia gravis (terminated appraisal) |
| Eculizumab |
09.01.03 |
Formulary
|
NICE TA647: Eculizumab for treating relapsing neuromyelitis optica (terminated appraisal) |
| Edoxaban |
02.08.02 |
Formulary
|
NICE TA355:Edoxaban for preventing stroke/systemic embolism in non‑valvular atrial fibrillation |
| Edoxaban |
02.08.02 |
Formulary
|
NICE TA354: Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism |
| Efanesoctocog alfa |
02.11 |
Formulary
|
NICE TA1051: Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A in people 2 years and over |
| Efgartigimod alfa |
10.02 |
Non Formulary
|
NICE TA1069: Efgartigimod for treating antibody-positive generalised myasthenia gravis |
| Elacestrant |
08.03.04.01 |
Formulary
|
NICE TA1036: Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment |
| Eladocagene exuparvovec |
09.08.01 |
Formulary
|
NICE HST26: Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency |
| Elafibranor |
01.09.01 |
Formulary
|
NICE TA1016: Elafibranor for previously treated primary biliary cholangitis |
| Elbasvir & grazoprevir |
05.03.03.02 |
Formulary
|
NICE TA413: Elbasvir–grazoprevir for treating chronic hepatitis C |
| Eliglustat |
09.08.01 |
Formulary
|
NICE HST5 Eliglustat for treating type 1 Gaucher disease |
| Elosulfase alfa |
09.08.01 |
Formulary
|
NICE HST19: Elosulfase alfa for treating mucopolysaccharidosis type 4A |
| Elranatamab |
08.01.05 |
Formulary
|
NICE TA1023: Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments |
| Eltrombopag |
09.01.04 |
Formulary
|
NICE TA293: Eltrombopag for treating chronic ITP |
| Eluxadoline |
01.04.02 |
Non Formulary
|
NICE TA471 Eluxadoline for treating irritable bowel syndrome with diarrhoea |
| Empagliflozin |
06.01.02.03 |
Formulary
|
NICE NG18: Diabetes (type 1 and type 2) in children and young people: diagnosis and management |
| Empagliflozin |
06.01.02.03 |
Formulary
|
NICE TA942: Empagliflozin for treating chronic kidney disease |
| Empagliflozin |
06.01.02.03 |
Formulary
|
NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes |
| Empagliflozin |
06.01.02.03 |
Formulary
|
NICE TA336: Empagliflozin for type 2 diabetes |
| Empagliflozin |
02.15 |
Formulary
|
NICE TA773: Empagliflozin for treating chronic heart failure with reduced ejection fraction |
| Empagliflozin |
02.15 |
Formulary
|
NICE TA929: Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction |
| Encorafenib |
08.01.05 |
Formulary
|
NICE TA668: Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer |
| Encorafenib |
08.01.05 |
Formulary
|
NICE TA562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma |
| Enfortumab vedotin |
08.01.05 |
Formulary
|
TA1097: Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitable |
| Entecavir |
05.03.03.01 |
Formulary
|
NICE CG165: Hepatitis B (incorporates TA153) |
| Entecavir |
05.03.03.01 |
Formulary
|
NICE TA153: Hepatitis B (chronic) - etecavir |
| Entrectinib |
08.01.05 |
Formulary
|
NICE TA644 Entrectinib for treating NTRK fusion-positive solid tumours |
| Entrectinib |
08.01.05 |
Formulary
|
NICE TA643: Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer |
| Enzalutamide |
08.03.04.02 |
Formulary
|
NICE TA316: Enzalutamide for prostate cancer |
| Enzalutamide |
08.03.04.02 |
Formulary
|
NICE TA377: Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated |
| Enzalutamide |
08.03.04.02 |
Formulary
|
NICE TA712: Enzalutamide for treating hormone-sensitive metastatic prostate cancer |
| Epcoritamab |
08.01.05 |
Formulary
|
NICE TA954: Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments |
| Eplerenone |
02.02.03 |
Formulary
|
NICE NG106: Chronic heart failure in adults: diagnosis and management |
| Eplontersen |
04.12 |
Formulary
|
NICE TA1020: Eplontersen for treating hereditary transthyretin-related amyloidosis |
| Epoetin alfa |
09.01.03 |
Formulary
|
NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy |
| Epoetin alfa |
09.01.03 |
Formulary
|
NICE NG203: Chronic kidney disease: assessment and management |
| Epoetin beta |
09.01.03 |
Formulary
|
NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy |
| Epoetin beta |
09.01.03 |
Formulary
|
NICE NG203: Chronic kidney disease: assessment and management |
| Eptinezumab |
04.07.04.02 |
Formulary
|
NICE TA871: Eptinezumab for preventing migraine |
| Erdafitinib |
08.01.05 |
Formulary
|
NICE TA1062: Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor |
| Erenumab |
04.07.04.02 |
Formulary
|
NICE TA682: Erenumab for preventing migraine in adults |
| Eribulin |
08.01.05 |
Formulary
|
NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens |
| Erlotinib |
08.01.05 |
Formulary
|
NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy |
| Erlotinib |
08.01.05 |
Formulary
|
NICE TA258: Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer |
| Erlotinib |
08.01.05 |
Formulary
|
NICE TA227: Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer |
| Ertugliflozin |
06.01.02.03 |
Formulary
|
NICE TA583: Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes |
| Ertugliflozin |
06.01.02.03 |
Formulary
|
NICE TA572: Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes |
| Etanercept |
10.01.03 |
Non Formulary
|
NICE TA35: Adult psoriasis |
| Etanercept |
10.01.03 |
Non Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Etanercept |
10.01.03 |
Non Formulary
|
NICE TA195: rheumatoid arthritis after the failure of a TNF inhibitor |
| Etanercept |
10.01.03 |
Non Formulary
|
NICE TA199: Psoriatic arthritis |
| Etanercept |
10.01.03 |
Non Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Etanercept |
13.05.03 |
Formulary
|
NICE TA455 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
| Etanercept |
13.05.03 |
Formulary
|
NICE TA103: Psoriasis - efalizumab and etanercept |
| Etanercept |
10.01.03 |
Formulary
|
NICE TA715: Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed |
| Etanercept |
10.01.03 |
Formulary
|
NICE TA199: Psoriatic arthritis |
| Etanercept |
10.01.03 |
Formulary
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for JIA |
| Etanercept |
10.01.03 |
Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Etanercept |
10.01.03 |
Formulary
|
NICE TA195: Rheumatoid arthritis after the failure of a TNF inhibitor |
| Etanercept |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Etanercept |
10.01.03 |
Formulary
|
NICE TA35: Adult psoriasis |
| Etelcalcetide |
09.05.01.02 |
Formulary
|
NICE TA448 Etelcalcetide for treating secondary hyperparathyroidism |
| Etranacogene dezaparvovec |
02.11 |
Formulary
|
NICE TA989: Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B |
| Etrasimod |
01.05.03 |
Formulary
|
NICE TA956: Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over |
| Everolimus |
08.01.05 |
Formulary
|
NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy |
| Everolimus |
08.01.05 |
Formulary
|
NICE TA432: Everolimus (Afinitor) for advanced renal cell carcinoma after previous treatment |
| Everolimus |
08.01.05 |
Formulary
|
NICE TA449 Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease |
| Everolimus |
08.01.05 |
Formulary
|
NICE TA348: Everolimus for preventing organ rejection in liver transplantation |
| Everolimus |
08.01.05 |
Formulary
|
NICE TA481: Immunosuppressive therapy for kidney transplant in adults |
| Everolimus |
08.01.05 |
Formulary
|
NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma |
| Everolimus |
08.01.05 |
Formulary
|
NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people |
| Evinacumab |
02.12 |
Formulary
|
NICE TA1002 : Evinacumab for treating homozygous familial hypercholesterolaemia in people 12 years and over |
| Evolocumab |
02.12 |
Non Formulary
|
NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia |
| Evolocumab |
02.12 |
Formulary
|
NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia |
| Exagamglogene Autotemcel |
09.01 |
Formulary
|
NICE TA1003 : Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and over |
| Exagamglogene Autotemcel |
09.01 |
Formulary
|
NICE TA1044: Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and over |
| Exenatide prolonged release |
06.01.02.03 |
Non Formulary
|
NICE TA248: MR exenatide |
| Ezetimibe |
02.12 |
Formulary
|
NICE TA385: Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia |
| Faricimab |
11.08.02 |
Formulary
|
NICE TA1004: Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusion |
| Faricimab |
11.08.02 |
Formulary
|
NICE TA800: Faricimab for treating wet age-related macular degeneration |
| Faricimab |
11.08.02 |
Formulary
|
NICE TA799: Faricimab for treating diabetic macular oedema |
| Febuxostat |
10.01.04 |
Formulary
|
NICE NG219: Gout: diagnosis and management |
| Fedratinib |
08.01.05 |
Formulary
|
NICE TA1018: Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis |
| Fenfluramine |
04.08.01 |
Formulary
|
NICE TA1050: Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over |
| Fenfluramine |
04.08.01 |
Formulary
|
NICE TA808: Fenfluramine for treating seizures associated with Dravet syndrome |
| Filgotinib |
01.05.03 |
Formulary
|
NICE TA792: Filgotinib for treating moderately to severely active ulcerative colitis |
| Filgotinib |
10.01.03 |
Formulary
|
NICE TA676: Filgotinib for treating moderate to severe rheumatoid arthritis |
| Filgotinib |
10.01.03 |
Formulary
|
NICE TA792: Filgotinib for treating moderately to severely active ulcerative colitis |
| Finasteride 5mg tablets |
06.04.02 |
Formulary
|
NICE CG97 Lower urinary tract symptoms: quick reference guide |
| Finerenone |
02.02.03 |
Formulary
|
NICE TA877: Finerenone for treating chronic kidney disease in type 2 diabetes |
| Fingolimod |
08.02.04 |
Formulary
|
NICE TA254: Fingolimod for highly active relapsing remitting multiple sclerosis |
| Fludarabine Phosphate |
08.01.03 |
Formulary
|
NICE TA29: Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia |
| Fludarabine Phosphate |
08.01.03 |
Formulary
|
NICE TA119: Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia |
| Fluocinolone 190 microgram intravitreal implant |
11.04.01 |
Formulary
|
NICE TA590: Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis |
| Fluocinolone 190 microgram intravitreal implant |
11.04.01 |
Formulary
|
NICE TA613: Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy |
| Fluocinolone 190 microgram intravitreal implant |
11.04.01 |
Formulary
|
NICE TA301: Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy |
| Fluocinolone 190 microgram intravitreal implant |
11.04.01 |
Formulary
|
NICE TA953: Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema |
| Foslevidopa/foscarbidopa |
04.09.01 |
Formulary
|
NICE TA934: Foslevodopa–foscarbidopa for treating advanced Parkinson’s with motor symptoms |
| Fostamatinib |
08.01.05 |
Formulary
|
NICE TA835: Fostamatinib for treating refractory chronic immune thrombocytopenia |
| Fremanezumab |
04.07.04.02 |
Formulary
|
NICE TA764: Fremanezumab for preventing migraine |
| Fruquintinib |
08.01.05 |
Formulary
|
NICE TA1079: Fruquintinib for previously treated metastatic colorectal cancer |
| Fulvestrant |
08.03.04.01 |
Formulary
|
NICE TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer |
| Futibatinib |
08.01.05 |
Formulary
|
NICE TA1005 : Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement |
| Galantamine |
04.11 |
Formulary
|
NICE TA217: Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease |
| Galcanezumab |
04.07.04.02 |
Formulary
|
NICE TA659: Galcanezumab for preventing migraine |
| Ganaxolone |
04.08.01 |
Non Formulary
|
NICE TA1033: Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over |
| Gefapixant |
03.09.01 |
Non Formulary
|
NICE TA969: Gefapixant for treating refractory or unexplained chronic cough (terminated appraisal) |
| Gefitinib |
08.01.05 |
Formulary
|
NICE TA192: Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer |
| Gefitinib |
08.01.05 |
Formulary
|
NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy |
| Gemcitabine |
08.01.03 |
Formulary
|
NICE NG85: Pancreatic cancer in adults: diagnosis and management |
| Gemcitabine |
08.01.03 |
Formulary
|
NICE TA116: Gemcitabine for the treatment of metastatic breast cancer |
| Gemcitabine |
08.01.03 |
Formulary
|
NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
| Gemtuzumab ozogamicin |
08.01.05 |
Formulary
|
NICE TA545: Gemtuzumab ozogamicin for untreated acute myeloid leukaemia |
| Gilteritinib |
08.01.05 |
Formulary
|
NICE TA642: Gilteritinib for treating relapsed or refractory acute myeloid leukaemia |
| Givosiran |
09.08.02 |
Formulary
|
NICE HST 16: Givosiran for treating acute hepatic porphyria |
| Glatiramer Acetate |
08.02.04 |
Formulary
|
NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis |
| Glecaprevir & Pibrentasvir |
05.03.03.02 |
Formulary
|
NICE TA499: Glecaprevir–pibrentasvir for treating chronic hepatitis C |
| GLIADEL wafer Carmustine 7.6mg |
20 |
Non Formulary
|
NICE TA121: Glioma - carmustine implants and temozolomide |
| Glofitamab |
08.01.05 |
Formulary
|
NICE TA927: Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments |
| Glycopyrronium bromide |
01.02 |
Restricted Use
|
NICE NG71: Parkinson’s disease in adults |
| Golimumab |
01.05.03 |
Formulary
|
NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis |
| Golimumab |
10.01.03 |
Formulary
|
NICE TA220: psoriatic arthritis |
| Golimumab |
10.01.03 |
Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Golimumab |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Golimumab |
10.01.03 |
Formulary
|
NICE TA497: Golimumab for treating non-radiographic axial spondyloarthritis |
| Guselkumab |
13.05.03 |
Formulary
|
NICE TA521: Guselkumab for treating moderate to severe plaque psoriasis |
| Guselkumab |
01.05.03 |
Formulary
|
NICE TA1094: Guselkumab for treating moderately to severely active ulcerative colitis |
| Guselkumab |
01.05.03 |
Formulary
|
NICE TA1095: Guselkumab for previously treated moderately to severely active Crohn’s disease |
| Guselkumab |
10.01.03 |
Formulary
|
NICE TA815: Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs |
| Haloperidol |
21.04 |
Formulary
|
NICE NG10: Violence and aggression: short-term management in mental health, health and community settings |
| Haloperidol |
04.02.01 |
Formulary
|
NICE NG10: Violence and aggression: short-term management in mental health, health and community settings |
| House dust mite allergen immunotherapy |
03.04.02 |
Formulary
|
NICE TA1045: 12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites |
| Hydroxocobalamin 1mg in 1ml injection |
09.01.02 |
Formulary
|
NICE NG239: Vitamin B12 deficiency in over 16s: diagnosis and management |
| Ibandronic Acid |
06.06.02 |
Formulary
|
NICE TA464 Bisphosphonates for treating osteoporosis |
| Ibrutinib |
08.01.05 |
Formulary
|
NICE TA891: Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia |
| Ibrutinib |
08.01.05 |
Formulary
|
NICE TA795: Ibrutinib for treating Waldenstrom’s macroglobulinaemia |
| Ibrutinib |
08.01.05 |
Formulary
|
NICE TA429: Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation |
| Ibrutinib |
08.01.05 |
Formulary
|
NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma |
| Icosapent ethyl |
02.12 |
Formulary
|
NICE TA805: Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides |
| Idebenone |
11.08 |
Formulary
|
TA1093: Idebenone for treating visual impairment in Leber’s hereditary optic neuropathy in people 12 years and over |
| Idecabtagene vicleucel |
08.01.05 |
Non Formulary
|
NICE TA936: Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma after 3 or more treatments (terminated appraisal) |
| Idelalisib |
08.01.05 |
Formulary
|
NICE TA359: Chronic lymphocytic leukaemia - Idelalisib |
| Imatinib |
08.01.05 |
Formulary
|
NICE TA326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours |
| Imatinib |
08.01.05 |
Formulary
|
NICE TA209: Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours |
| Imatinib |
08.01.05 |
Formulary
|
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia |
| Imatinib |
08.01.05 |
Formulary
|
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia |
| Imatinib |
08.01.05 |
Formulary
|
NICE TA70: Guidance on the use of imatinib for chronic myeloid leukaemia |
| Imatinib |
08.01.05 |
Formulary
|
NICE TA86: Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours |
| Imlifidase |
08.01.05 |
Formulary
|
NICE TA809: Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease |
| Inclisiran |
02.12 |
Formulary
|
NICE TA 733 - Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia |
| Infliximab |
10.01.03 |
Formulary
|
NICE TA195: Rheumatoid arthritis (after failure of a TNF inhibitor) |
| Infliximab |
10.01.03 |
Formulary
|
NICE TA199: Psoriatic arthritis |
| Infliximab |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Infliximab |
10.01.03 |
Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Infliximab |
10.01.03 |
Formulary
|
NICE TA715: Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed |
| Infliximab |
13.05.03 |
Formulary
|
NICE TA134: Infliximab for psoriasis |
| Infliximab |
01.05.03 |
Formulary
|
NICE TA187: Crohns disease - infliximab & adalimumab |
| Infliximab |
01.05.03 |
Formulary
|
NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis |
| Infliximab |
01.05.03 |
Formulary
|
NICE TA163: Ulcerative colitis (acute manifestations) Infliximab |
| Inotersen |
04.12 |
Formulary
|
NICE HST9: Inotersen for treating hereditary transthyretin amyloidosis |
| Inotuzumab ozogamicin |
08.01.05 |
Formulary
|
NICE TA541: Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia |
| Insulin Glargine biosimilar Abasaglar® |
06.01.01.02 |
Formulary
|
NG17: Type 1 diabetes in adults: diagnosis and management |
| Interferon beta |
08.02.04 |
Formulary
|
NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis |
| Interferon Beta |
08.02.04 |
Formulary
|
NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis |
| Interferon Beta |
08.02.04 |
Formulary
|
NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis |
| Interferon Beta |
08.02.04 |
Formulary
|
NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis |
| Ipilimumab |
08.01.05 |
Formulary
|
NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma |
| Ipilimumab |
08.01.05 |
Formulary
|
NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma |
| Ipilimumab |
08.01.05 |
Formulary
|
NICE TA357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab |
| Ipilimumab |
08.01.05 |
Formulary
|
NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma |
| Ipilimumab |
08.01.05 |
Formulary
|
NICE TA780: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma |
| Iptacopan |
09.01.03 |
Formulary
|
NICE TA1000 : Iptacopan for treating paroxysmal nocturnal haemoglobinuria |
| Isatuximab |
08.01.05 |
Formulary
|
NICE TA658: Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma |
| Isatuximab |
08.01.05 |
Formulary
|
NICE TA1098: Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable |
| Ivabradine |
02.06.03 |
Formulary
|
NICE TA267: Ivabradine for treating chronic heart failure |
| Ivabradine |
02.06.03 |
Formulary
|
NICE CG126: Guidance on Stable Angina (2011) |
| Ivosidenib |
08.01.05 |
Formulary
|
NICE TA979: Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation |
| Ivosidenib |
08.01.05 |
Formulary
|
NICE TA948: Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments |
| Ixazomib |
08.01.05 |
Formulary
|
NICE TA870: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma |
| Ixekizumab |
10.01.03 |
Formulary
|
NICE TA537: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs |
| Ixekizumab |
10.01.03 |
Formulary
|
NICE TA718: Ixekizumab for treating axial spondyloarthritis |
| Ixekizumab |
13.05.03 |
Formulary
|
NICE TA442 Ixekizumab for treating moderate to severe plaque psoriasis |
| Lamivudine |
05.03.03.01 |
Formulary
|
NICE CG165: Chronic Hepatitis B |
| Lanadelumab |
03.04.03 |
Formulary
|
NICE TA606: Lanadelumab for preventing recurrent attacks of hereditary angioedema |
| Lapatinib |
08.01.05 |
Formulary
|
NICE TA257: Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer that overexpresses HER2 |
| Larotrectinib |
08.01.05 |
Formulary
|
NICE TA630: Larotrectinib for treating NTRK fusion-positive solid tumours |
| Latanoprost 50microgram/ml with Netarsudil 200microgram/ml eye drops |
11.06 |
Formulary
|
NICE TA1009: Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension |
| Lebrikizumab |
13.05.03 |
Formulary
|
NICE TA986: Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over |
| Lenalidomide |
08.02.04 |
Formulary
|
NICE TA322: Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality |
| Lenalidomide |
08.02.04 |
Formulary
|
NICE TA587: Lenalidomide plus dexamethasone for previously untreated multiple myeloma |
| Lenalidomide |
08.02.04 |
Formulary
|
NICE TA586: Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib |
| Lenalidomide |
08.02.04 |
Formulary
|
NICE TA680: Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma |
| Lenalidomide |
08.02.04 |
Formulary
|
NICE TA171: Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapies |
| Lenalidomide |
08.02.04 |
Formulary
|
NICE TA27: Lenalidomide with rituximab for previously treated follicular lymphoma |
| Leniolisib |
09.08.01 |
Formulary
|
NICE HST33: Leniolisib for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over |
| Lenvatinib |
08.01.05 |
Formulary
|
NICE TA858: Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma |
| Lenvatinib |
08.01.05 |
Formulary
|
NICE TA 551: Lenvatinib for untreated advanced hepatocellular carcinoma |
| Lenvatinib |
08.01.05 |
Formulary
|
NICE TA 535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine |
| Lenvatinib |
08.01.05 |
Formulary
|
NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma |
| Letermovir |
05.03.02.02 |
Formulary
|
NICE TA591: Letermovir for preventing cytomegalovirus disease after a stem cell transplant |
| Linzagolix |
06.07.02 |
Formulary
|
NICE TA996 : Linzagolix for treating moderate to severe symptoms of uterine fibroids |
| Liraglutide |
04.05.01 |
Formulary
|
NICE TA664: Liraglutide for managing overweight and obesity |
| Liraglutide |
06.01.02.03 |
Formulary
|
NICE NG28: Type 2 diabetes in adults: management |
| Liraglutide |
06.01.02.03 |
Formulary
|
NICE TA664: Liraglutide for managing overweight and obesity |
| Liraglutide |
06.01.02.03 |
Formulary
|
NICE NG18: Diabetes (type 1 and type 2) in children and young people: diagnosis and management |
| Lisocabtagene maraleucel |
08.01.05 |
Formulary
|
NICE TA1048: Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after first-line chemoimmunotherapy when a stem cell transplant is suitable |
| Lisocabtagene maraleucel |
08.01.05 |
Non Formulary
|
NICE TA987:Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (terminated appraisal) |
| Loncastuximab tesirine |
08.01.05 |
Formulary
|
NICE TA947: Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments |
| Lorlatinib |
08.01.05 |
Formulary
|
NICE TA628: Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer |
| Lubiprostone |
01.06.07 |
Non Formulary
|
NICE TA318: Lubiprostone for treating chronic idiopathic constipation |
| Lumacaftor and Ivacaftor |
03.07 |
Formulary
|
NICE TA988: Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis |
| Lumasiran |
09.08.01 |
Formulary
|
NICE HST25: Lumasiran for treating primary hyperoxaluria type 1 |
| Lusutrombopag |
09.01.04 |
Formulary
|
NICE TA617: Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure |
| Lutetium (177Lu) |
08.01.05 |
Formulary
|
NICE TA539: Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours |
| Lutetium (177Lu) |
08.01.05 |
Formulary
|
NICE TA930: Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments |
| Mannitol inhalation |
03.07 |
Formulary
|
NICE TA266: Cystic fibrosis - mannitol dry powder for inhalation |
| Maribavir |
05.03.02.02 |
Formulary
|
NICE TA860: Maribavir for treating refractory cytomegalovirus infection after transplant |
| Marstacimab |
02.11 |
Formulary
|
NICE TA1073: Marstacimab for treating severe haemophilia A or B in people 12 years and over without anti-factor antibodies |
| Marstacimab |
02.11 |
Non Formulary
|
NICE TA1073: Marstacimab for treating severe haemophilia A or B in people 12 years and over without anti-factor antibodies |
| Mavacamten |
02.16 |
Formulary
|
NICE TA913: Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy |
| Melphalan |
08.01.01 |
Formulary
|
NICE TA822: Melphalan for haematological diseases before allogeneic haematopoietic stem cell transplant (terminated appraisal) |
| Melphalan flufenamide |
08.01.01 |
Non Formulary
|
NICE TA968:Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) |
| Memantine |
04.11 |
Formulary
|
NICE TA217: Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease |
| Mepolizumab |
03.04.02 |
Formulary
|
NICE TA671: Mepolizumab for treating severe eosinophilic asthma |
| Methylprednisolone sodium succinate 40mg, 125mg, 500mg & 1000mg |
06.03.02 |
Formulary
|
NICE NG220: Multiple sclerosis in adults: management |
| Metreleptin |
06.08 |
Formulary
|
NICE HST14: Metreleptin for treating lipodystrophy |
| Mexiletine |
10.02 |
Formulary
|
NICE TA748: Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders |
| Midostaurin |
08.01.05 |
Formulary
|
NICE TA728: Midostaurin for treating advanced systemic mastocytosis |
| Midostaurin |
08.01.05 |
Formulary
|
NICE TA523 Midostaurin for untreated acute myeloid leukaemia |
| Mifamurtide |
08.02.04 |
Formulary
|
NICE TA235: Osteosarcoma - mifamurtide: guidance |
| Migalastat |
09.08.01 |
Formulary
|
NICE HST4: Migalastat for treating Fabry disease |
| Mirabegron |
07.04.02 |
Formulary
|
NICE TA290: Mirabegron for overactive bladder |
| Mirikizumab |
01.05.03 |
Formulary
|
NICE TA1080: Mirikizumab for previously treated moderately to severely active Crohn’s disease |
| Mirikizumab |
01.05.03 |
Formulary
|
NICE TA925: Mirikizumab for treating moderately to severely active ulcerative colitis |
| Mobocertinib |
08.01.05 |
Formulary
|
NICE TA855: Mobocertinib for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy |
| Mogamulizumab |
08.01.05 |
Formulary
|
NICE TA754: Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome |
| Molnupiravir |
05.03.06 |
Restricted Use
|
TA1056: Molnupiravir for treating COVID-19 |
| Momelotinib |
08.01.05 |
Formulary
|
NICE TA957: Momelotinib for treating myelofibrosis-related splenomegaly or symptoms |
| Mosunetuzumab |
08.01.05 |
Non Formulary
|
NICE TA892: Mosunetuzumab for treating relapsed or refractory follicular lymphoma |
| Mycophenolate Mofetil |
08.02.01 |
Formulary
|
NICE TA481: Immunosuppressive therapy for kidney transplant in adults |
| Naftidrofuryl |
02.06.04 |
Formulary
|
NICE TA223: Intermittent claudication drugs |
| Naftidrofuryl |
02.06.04 |
Formulary
|
NICE CG147: Lower limb peripheral arterial disease management |
| Naldemedine |
01.06.06 |
Formulary
|
NICE TA651 - Naldemedine for treating opioid-induced constipation |
| Nalmefene |
04.10.01 |
Formulary
|
NICE TA325: Nalmefene for reducing alcohol consumption in people with alcohol dependence |
| Naloxegol |
01.06.06 |
Formulary
|
NICE TA345: Naloxegol for treating opioid‑induced constipation |
| Naltrexone 50 mg tablets |
04.10.03 |
Formulary
|
NICE TA115: Drug misuse - naltrexone |
| Naltrexone/ bupropion |
04.05.01 |
Non Formulary
|
NICE TA494: Naltrexone–bupropion for managing overweight and obesity |
| Natalizumab |
08.02.04 |
Formulary
|
NICE TA127: Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis |
| Necitumumab |
08.01.05 |
Formulary
|
NICE TA411: Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer |
| Nemolizumab |
13.05.03 |
Formulary
|
NICE TA1077: Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over |
| Neratinib |
08.01.05 |
Formulary
|
NICE TA612: Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab |
| Nilotinib |
08.01.05 |
Formulary
|
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia |
| Nilotinib |
08.01.05 |
Formulary
|
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia |
| Nintedanib |
03.11 |
Formulary
|
NICE TA379:Nintedanib for treating idiopathic pulmonary fibrosis |
| Nintedanib |
03.11 |
Formulary
|
NICE TA747: Nintedanib for treating progressive fibrosing interstitial lung diseases |
| Nintedanib |
08.01.05 |
Formulary
|
NICE TA347: Recurrent non-small-cell lung cancer |
| Nintedanib |
08.01.05 |
Formulary
|
NICE TA747 Nintedanib for treating progressive fibrosing interstitial lung diseases |
| Nintedanib |
08.01.05 |
Formulary
|
NICE TA379: Nintedanib for treating idiopathic pulmonary fibrosis |
| Nintedanib |
08.01.05 |
Formulary
|
NICE TA864: Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted |
| Niraparib |
08.01.05 |
Formulary
|
NICE TA784: Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer |
| Niraparib |
08.01.05 |
Formulary
|
NICE TA673: Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy |
| Nirmatrelvir and Ritonavir |
05.03.06 |
Formulary
|
NICE TA878: Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 |
| Nivolumab |
08.01.05 |
Non Formulary
|
NICE TA980: Nivolumab for adjuvant treatment of completely resected melanoma at high risk of recurrence in people 12 years and over (terminated appraisal) |
| Nivolumab |
08.01.05 |
Formulary
|
NICE TA462 Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma |
| Nivolumab |
08.01.05 |
Formulary
|
NICE TA417: Nivolumab for previously treated advanced renal cell carcinoma |
| Nivolumab |
08.01.05 |
Formulary
|
NICE TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma |
| Nivolumab |
08.01.05 |
Formulary
|
NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma |
| Nivolumab |
08.01.05 |
Formulary
|
NICE TA964: Cabozantinib with nivolumab for untreated advanced renal cell carcinoma |
| Nivolumab |
08.01.05 |
Formulary
|
NICE TA1065:Nivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency |
| Nivolumab |
08.01.05 |
Formulary
|
NICE TA818: Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma |
| Nivolumab |
08.01.05 |
Formulary
|
NICE TA713: Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy |
| Nivolumab |
08.01.05 |
Formulary
|
NICE TA865: Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma |
| Nivolumab |
08.01.05 |
Formulary
|
NICE TA876: Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer |
| Nivolumab |
08.01.05 |
Formulary
|
NICE TA530: Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy |
| Nivolumab |
08.01.05 |
Formulary
|
NICE TA724: Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small- cell lung cancer |
| Nivolumab |
08.01.05 |
Formulary
|
NICE TA655: Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy |
| Nivolumab |
08.01.05 |
Formulary
|
NICE TA684: Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease |
| Nivolumab |
08.01.05 |
Formulary
|
NICE TA707: Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer |
| Nivolumab |
08.01.05 |
Formulary
|
NICE TA817: Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence |
| Nivolumab |
08.01.05 |
Formulary
|
NICE TA746: Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer |
| Nivolumab |
08.01.05 |
Formulary
|
NICE TA780: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma |
| Nivolumab |
08.01.05 |
Formulary
|
NICE TA716: Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency |
| Nivolumab |
08.01.05 |
Formulary
|
NICE TA736: Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy |
| Nivolumab-relatlimab |
08.01.05 |
Formulary
|
NICE TA950: Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over |
| Nusinersen |
10.02 |
Formulary
|
NICE TA588: Nusinersen for treating spinal muscular atrophy |
| Obeticholic acid |
01.09.01 |
Formulary
|
NICE TA443 Obeticholic acid for treating primary biliary cholangitis |
| Obinutuzumab |
08.02.03 |
Formulary
|
NICE TA343: Obinutuzumab with chlorambucil for CLL |
| Obinutuzumab |
08.02.03 |
Formulary
|
NICE TA629: Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab |
| Ocrelizumab |
08.02.03 |
Formulary
|
NICE TA 533: Ocrelizumab for treating relapsing–remitting multiple sclerosis |
| Ocrelizumab |
08.02.03 |
Formulary
|
NICE TA585: Ocrelizumab for treating primary progressive multiple sclerosis |
| Ocriplasmin |
11.08.02 |
Formulary
|
NICE TA 297 Ocriplasmin for treating vitreomacular traction |
| Odevixibat |
01.09.01 |
Formulary
|
NICE HST17: Odevixibat for treating progressive familial intrahepatic cholestasis |
| Ofatumumab |
08.02.03 |
Formulary
|
NICE TA699: Ofatumumab for treating relapsing multiple sclerosis |
| Olaparib |
08.01.05 |
Formulary
|
NICE TA962: Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy |
| Olaparib |
08.01.05 |
Formulary
|
NICE TA886: Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy |
| Olaparib |
08.01.05 |
Formulary
|
NICE TA887: Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer |
| Olaparib |
08.01.05 |
Formulary
|
NICE TA908: Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy |
| Olaparib |
08.01.05 |
Formulary
|
NICE TA951: Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer |
| Olaparib |
08.01.05 |
Formulary
|
NICE TA946: Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer |
| Olaparib |
08.01.05 |
Formulary
|
NICE TA1040: Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy |
| Olipudase alfa |
09.08.01 |
Non Formulary
|
NICE HST32: Olipudase alfa for treating acid sphingomyelinase deficiency (Niemann–Pick disease) type AB and type B |
| Omalizumab |
03.04.02 |
Formulary
|
NICE TA278: Omalizumab for treating allergic asthma |
| Omalizumab |
03.04.02 |
Formulary
|
NICE TA339: Omalizumab for previously treated chronic spontaneous urticaria |
| Omalizumab |
03.04.02 |
Formulary
|
NICE TA678: Omalizumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal) |
| Ombitasvir & paritaprevir & ritonavir |
05.03.03.02 |
Non Formulary
|
NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C |
| Onasemnogene abeparvovec |
19 |
Formulary
|
NICE HST15: Onasemnogene abeparvovec for treating spinal muscular atrophy |
| Onasemnogene abeparvovec |
19 |
Formulary
|
NICE HST24: Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophy |
| Oseltamivir |
05.03.04 |
Formulary
|
NICE TA168: Amantadine, oseltamivir and zanamivir for the treatment of influenza |
| Oseltamivir |
05.03.04 |
Formulary
|
NICE TA158: Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza |
| Osimertinib |
08.02.04 |
Formulary
|
NICE TA654: Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer |
| Osimertinib |
08.02.04 |
Formulary
|
NICE TA1043: Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection |
| Osimertinib |
08.02.04 |
Formulary
|
NICE TA 653: Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer |
| Osimertinib |
08.02.04 |
Formulary
|
NICE TA1060: Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer |
| Oxaliplatin |
08.01.05 |
Formulary
|
NICE TA100: Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes’ C) colon cancer |
| Ozanimod |
01.05.03 |
Formulary
|
NICE TA 828: Ozanimod for treating moderately to severely active ulcerative colitis |
| Paclitaxel |
08.01.05 |
Formulary
|
NICE TA55: Guidance on the use of paclitaxel in the treatment of ovarian cancer |
| Paclitaxel |
08.01.05 |
Formulary
|
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
| Paclitaxel - Albumin Bound Formulation |
08.01.05 |
Formulary
|
NICE TA476 Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer |
| Palbociclib |
08.03.04.01 |
Formulary
|
NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer |
| Palbociclib |
08.03.04.01 |
Formulary
|
NICE TA836: Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy |
| Paliperidone |
04.02.02 |
Formulary
|
NICE CG178: Psychosis and schizophrenia in adults: prevention and management |
| Panitumumab |
08.01.05 |
Formulary
|
NICE TA439 Cetuximab and panitumumab for previously untreated metastatic colorectal cancer |
| Panobinostat |
08.01.05 |
Formulary
|
NICE TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments |
| Patiromer calcium (as Patiromer sorbitex calcium) |
09.02.01.01 |
Formulary
|
NICE TA623: Patiromer for treating hyperkalaemia |
| Patisiran |
04.12 |
Formulary
|
NICE HST10: Patisiran for treating hereditary transthyretin amyloidosis |
| Pazopanib |
08.01.05 |
Formulary
|
NICE TA215: Pazopanib in renal cell cancer |
| Peanut Allergy |
03.04.02 |
Formulary
|
NICE TA769: Palforzia for treating peanut allergy in children and young people |
| Pegaspargase 3750iu vial |
08.01.05 |
Formulary
|
NICE TA408: Pegaspargase for treating acute lymphoblastic leukaemia |
| Pegcetacoplan |
09.01.03 |
Formulary
|
NICE TA778: Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria |
| Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA96: Hepatitis B - peginterferon alfa |
| Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA300: Hepatitis C - peginterferon alfa |
| Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA75: Hepatitis C - pegylated interferons, ribavirin & alfa interferon |
| Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA200: Hepatitis C - peginterferon alfa & ribavirin |
| Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA106: Hepatitis C - peginterferon alfa & ribavirin |
| Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE CG165: Hepatitis B (chronic): diagnosis and management |
| Peginterferon Beta-1a |
08.02.04 |
Formulary
|
NICE TA624: Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis |
| Pegloticase |
20 |
Non Formulary
|
NICE TA291: Pegloticase not recommended for severe chronic gout |
| Pegunigalsidase alfa |
09.08.01 |
Formulary
|
NICE TA915: Pegunigalsidase alfa for treating Fabry’s disease |
| Pembrolizumab |
08.01.05 |
Non Formulary
|
NICE TA661: Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma |
| Pembrolizumab |
08.01.05 |
Non Formulary
|
NICE TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer |
| Pembrolizumab |
08.01.05 |
Non Formulary
|
NICE TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab |
| Pembrolizumab |
08.01.05 |
Non Formulary
|
NICE TA904: Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer |
| Pembrolizumab |
08.01.05 |
Non Formulary
|
NICE TA709: Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency |
| Pembrolizumab |
08.01.05 |
Non Formulary
|
NICE TA801: Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer |
| Pembrolizumab |
08.01.05 |
Non Formulary
|
NICE TA830: Pembrolizumab for adjuvant treatment of renal cell carcinoma |
| Pembrolizumab |
08.01.05 |
Non Formulary
|
NICE TA766: Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma |
| Pembrolizumab |
08.01.05 |
Non Formulary
|
NICE TA770: Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer |
| Pembrolizumab |
08.01.05 |
Non Formulary
|
NICE TA692: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy |
| Pembrolizumab |
08.01.05 |
Non Formulary
|
NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy |
| Pembrolizumab |
08.01.05 |
Non Formulary
|
NICE TA772: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies |
| Pembrolizumab |
08.01.05 |
Non Formulary
|
NICE TA837: Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma |
| Pembrolizumab |
08.01.05 |
Non Formulary
|
NICE TA737: Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer |
| Pembrolizumab |
08.01.05 |
Non Formulary
|
NICE TA683: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer |
| Pembrolizumab |
08.01.05 |
Non Formulary
|
NICE TA885: Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer |
| Pembrolizumab |
08.01.05 |
Non Formulary
|
NICE TA967: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over |
| Pembrolizumab |
08.01.05 |
Non Formulary
|
NICE TA914: Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency |
| Pembrolizumab |
08.01.05 |
Non Formulary
|
NICE TA939: Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer |
| Pembrolizumab |
08.01.05 |
Non Formulary
|
NICE TA983: Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma |
| Pembrolizumab |
08.01.05 |
Non Formulary
|
NICE TA966: Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal) |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA1092: Pembrolizumab with carboplatin and paclitaxel for untreated primary advanced or recurrent endometrial cancer |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA967: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA1017: Pembrolizumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA939: Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA1037: Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA914: Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA997: Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA683: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA737: Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA837: Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA801: Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA830: Pembrolizumab for adjuvant treatment of renal cell carcinoma |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA709: Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA766: Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA770: Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA772: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA692: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA661: Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA904: Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab |
| Pemetrexed |
08.01.03 |
Formulary
|
NICE TA402: Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin |
| Pemetrexed |
08.01.03 |
Formulary
|
NICE TA124: Pemetrexed for the treatment of non-small-cell lung cancer |
| Pemetrexed |
08.01.03 |
Formulary
|
NICE TA190: Pemetrexed for the maintenance treatment of non-small-cell lung cancer |
| Pemetrexed |
08.01.03 |
Formulary
|
NICE TA181: Pemetrexed for the first-line treatment of non-small-cell lung cancer |
| Pemetrexed |
08.01.03 |
Formulary
|
NICE TA135: Pemetrexed for the treatment of malignant pleural mesothelioma |
| Pemigatinib |
08.01.05 |
Formulary
|
NICE TA722: Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement |
| Pentosan Polysulphate Sodium |
07.04.03 |
Formulary
|
NICE TA610: Pentosan polysulfate sodium for treating bladder pain syndrome |
| Perampanel |
04.08.01 |
Non Formulary
|
NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care |
| Pertuzumab |
08.01.05 |
Formulary
|
NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer |
| Pertuzumab |
08.01.05 |
Formulary
|
NICE TA569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer |
| Pertuzumab |
08.01.05 |
Formulary
|
NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer |
| Pimecrolimus cream |
13.05.03 |
Formulary
|
NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema) |
| Pirfenidone |
03.11 |
Formulary
|
NICE TA504: Idiopathic pulmonary fibrosis - pirfenidone |
| Pitolisant |
04.04 |
Formulary
|
NICE TA776: Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea (NOT RECOMMENDED BY NICE) |
| Pixantrone |
08.01.02 |
Formulary
|
NICE TA306: Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin’s B‑cell lymphoma |
| Polatuzumab vedotin |
08.01.05 |
Formulary
|
NICE TA649: Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma |
| Polatuzumab vedotin |
08.01.05 |
Formulary
|
NICE TA874: Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma |
| Pomalidomide |
08.01.05 |
Formulary
|
NICE TA427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib |
| Pomalidomide |
08.02.04 |
Formulary
|
NICE TA427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib |
| Ponatinib |
08.01.05 |
Formulary
|
NICE TA451 Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia |
| Ponesimod |
08.02.04 |
Formulary
|
NICE TA767: Ponesimod for treating relapsing–remitting multiple sclerosis |
| Prasugrel |
02.09 |
Formulary
|
NICE TA317 (replaces TA182): Acute coronary syndrome - prasugrel |
| Prucalopride |
01.06.07 |
Formulary
|
NICE TA211: Constipation (women) - prucalopride |
| Quizartinib |
08.01.05 |
Formulary
|
NICE TA1013: Quizartinib for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia |
| Radium-223 dichloride |
08.03.04.02 |
Formulary
|
NICE TA412: Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases |
| Raloxifene Hydrochloride |
06.04.01.01 |
Formulary
|
NICE TA160: Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women (Not Approved) |
| Raloxifene Hydrochloride |
06.04.01.01 |
Formulary
|
NICE TA161: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women |
| Ramucirumab |
08.01.05 |
Formulary
|
NICE TA403: Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer |
| Ramucirumab |
08.01.05 |
Formulary
|
NICE TA378: Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy |
| Ranibizumab 10mg/1ml injection |
11.08.02 |
Formulary
|
NICE TA 298 Ranibizumab for treating choroidal neovascularisation associated with pathological myopia |
| Ranibizumab 10mg/1ml injection |
11.08.02 |
Formulary
|
NICE TA 283 Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion |
| Ranibizumab 10mg/1ml injection |
11.08.02 |
Formulary
|
NICE TA 155 Ranibizumab and pegaptanib for the treatment of age-related macular degeneration |
| Ranibizumab 10mg/1ml injection |
11.08.02 |
Formulary
|
NICE TA 274 Ranibizumab for treating diabetic macular oedema |
| Ranolazine |
02.06.03 |
Formulary
|
NICE CG126: Guidance on Stable Angina (2011) |
| Ravulizumab |
10.02.01 |
Non Formulary
|
NICE TA940: Ravulizumab for treating generalised myasthenia gravis (terminated appraisal) |
| Ravulizumab |
10.02.01 |
Non Formulary
|
NICE TA941: Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder (terminated appraisal) |
| Ravulizumab |
09.01.03 |
Formulary
|
NICE TA698: Ravulizumab for treating paroxysmal nocturnal haemoglobinuria |
| Ravulizumab |
09.01.03 |
Formulary
|
NICE TA710: Ravulizumab for treating atypical haemolytic uraemic syndrome |
| Regorafenib |
08.01.05 |
Formulary
|
NICE TA866: Regorafenib for previously treated metastatic colorectal cancer |
| Regorafenib |
08.01.05 |
Formulary
|
NICE TA555: Regorafenib for previously treated advanced hepatocellular carcinoma |
| Regorafenib |
08.01.05 |
Formulary
|
NICE TA 488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours |
| Relugolix |
08.03.04.02 |
Formulary
|
NICE TA995 : Relugolix for treating hormone-sensitive prostate cancer |
| Relugolix–estradiol–norethisterone acetate |
06.07.02 |
Formulary
|
NICE TA832: Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids |
| Relugolix–estradiol–norethisterone acetate |
06.07.02 |
Formulary
|
NICE TA1057: Relugolix–estradiol–norethisterone for treating symptoms of endometriosis |
| Remdesivir |
05.03.06 |
Restricted Use
|
NICE TA971: Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 |
| Reslizumab |
03.04.02 |
Formulary
|
NICE TA479 Reslizumab for treating severe eosinophilic asthma |
| Retigabine |
04.08.01 |
Formulary
|
NICE TA232: Retigabine for the adjunctive treatment of adults with partial onset seizures in epilepsy with and without secondary generalisation |
| Ribavirin |
05.03.03.02 |
Formulary
|
NICE TA106: Hepatitis C - peginterferon alfa and ribavirin |
| Ribavirin |
05.03.03.02 |
Formulary
|
NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon |
| Ribavirin |
05.03.03.02 |
Formulary
|
NICE TA200: Hepatitis C - peginterferon alfa and ribavirin |
| Ribociclib |
08.03.04.01 |
Formulary
|
NICE TA687: Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy |
| Ribociclib |
08.03.04.01 |
Formulary
|
NICE TA1086: Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive HER2-negative early breast cancer at high risk of recurrence |
| Ribociclib |
08.03.04.01 |
Formulary
|
NICE TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer |
| Rifaximin |
05.01.07 |
Formulary
|
TA337: Rifaximin for preventing episodes of overt hepatic encephalopathy |
| Riluzole |
04.09.03 |
Formulary
|
NICE TA20: Motor neurone disease - riluzole |
| Rimegepant |
04.07.04.02 |
Formulary
|
NICE TA906: Rimegepant for preventing migraine |
| Rimegepant |
04.07.04.02 |
Formulary
|
NICE TA919: Rimegepant for treating migraine |
| Ripretinib |
08.01.05 |
Non Formulary
|
NICE TA881: Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments |
| Risankizumab |
01.05.03 |
Formulary
|
NICE TA888: Risankizumab for previously treated moderately to severely active Crohn’s disease |
| Risankizumab |
01.05.03 |
Formulary
|
NICE TA998: Risankizumab for treating moderately to severely active ulcerative colitis |
| Risankizumab |
13.05.03 |
Formulary
|
NICE TA596: Risankizumab for treating moderate to severe plaque psoriasis |
| Risdiplam |
10.02 |
Formulary
|
NICE TA755: Risdiplam for treating spinal muscular atrophy |
| Risedronate |
06.06.02 |
Formulary
|
NICE TA464 Bisphosphonates for treating osteoporosis |
| Ritlecitinib |
13.05.03 |
Formulary
|
NICE TA958: Ritlecitinib for treating severe alopecia areata in people 12 years and over |
| Rituximab |
08.02.03 |
Formulary
|
NICE TA137: Rituximab for the treatment of relapsed or refractory stage III or IV follicular non- Hodgkin’s lymphoma |
| Rituximab |
08.02.03 |
Formulary
|
NICE TA174: Rituximab for the first-line treatment of chronic lymphocytic leukaemia |
| Rituximab |
08.02.03 |
Formulary
|
NICE TA193: Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia |
| Rituximab |
08.02.03 |
Formulary
|
NICE TA226: Rituximab for the first-line maintenance treatment of follicular non-Hodgkin’s lymphoma |
| Rituximab |
08.02.03 |
Formulary
|
NICE TA243: Rituximab for the first-line treatment of stage III-IV follicular lymphoma |
| Rituximab |
10.01.03 |
Formulary
|
NICE TA195: Rheumatoid arthritis - after failure of a TNF inhibitor |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA256: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA261: Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA335: Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA170: Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA287: Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA607: Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease |
| Rivastigmine |
04.11 |
Formulary
|
NICE TA217: Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease |
| Rivastigmine Twice weekly patches |
04.11 |
Formulary
|
NICE TA217: Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease |
| Roflumilast |
03.03.03 |
Formulary
|
NICE TA461: Roflumilast for treating chronic obstructive pulmonary disease |
| Romiplostim |
09.01.04 |
Formulary
|
NICE TA221: Thrombocytopenic purpura - romiplostim |
| Romosozumab |
06.06.02 |
Formulary
|
NICE TA791: Romosozumab for treating severe osteoporosis |
| Roxadustat |
09.01.03 |
Formulary
|
NICE TA807: Roxadustat for treating symptomatic anaemia in chronic kidney disease |
| Rucaparib |
08.01.05 |
Formulary
|
NICE TA1007 : Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer |
| Rucaparib |
08.01.05 |
Formulary
|
NICE TA1055:Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy |
| Ruxolitinib |
13.05.03 |
Non Formulary
|
NICE TA1088: Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over |
| Ruxolitinib |
08.01.05 |
Formulary
|
NICE TA1054: Ruxolitinib for treating acute graft versus host disease that responds inadequately to corticosteroids in people 12 years and over |
| Ruxolitinib |
08.01.05 |
Formulary
|
NICE TA921: Ruxolitinib for treating polycythaemia vera |
| Ruxolitinib |
08.01.05 |
Formulary
|
NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis |
| Sacituzumab govitecan |
08.01.05 |
Formulary
|
NICE TA819: Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies |
| Sacubitril & valsartan |
02.05.05.02 |
Formulary
|
NICE TA388: Sacubitril valsartan for heart failure (updated 16/7/16 to include adoption resources) |
| Sapropterin dihydrochloride |
09.04.01 |
Formulary
|
NICE TA729: Sapropterin for treating hyperphenylalaninaemia in phenylketonuria |
| Sarilumab |
10.01.03 |
Formulary
|
NICE TA485: Sarilumab for moderate to severe rheumatoid arthritis |
| Satralizumab |
10.02.01 |
Non Formulary
|
NICE TA960: Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders |
| Sebelipase alfa |
09.08.01 |
Non Formulary
|
NICE TA961: Sebelipase alfa for treating lysosomal acid lipase deficiency that is not Wolman disease (terminated appraisal) |
| Sebelipase alfa |
09.08.01 |
Formulary
|
NICE HST30: Sebelipase alfa for treating Wolman disease |
| Secukinumab |
10.01.03 |
Formulary
|
NICE TA407: Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors |
| Secukinumab |
10.01.03 |
Formulary
|
NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs |
| Secukinumab |
10.01.03 |
Formulary
|
NICE TA719: Secukinumab for treating non-radiographic axial spondyloarthritis |
| Secukinumab |
13.05.03 |
Formulary
|
NICE TA350: Secukinumab for treating moderate to severe plaque psoriasis |
| Secukinumab |
13.05.03 |
Formulary
|
NICE TA734: Secukinumab for treating moderate to severe plaque psoriasis in children and young people |
| Secukinumab |
13.05.03 |
Formulary
|
NICE TA935: Secukinumab for treating moderate to severe hidradenitis suppurativa |
| Selinexor |
08.01.05 |
Formulary
|
NICE TA970: Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments |
| Selinexor |
08.01.05 |
Formulary
|
NICE TA974: Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma |
| Selinexor |
08.01.05 |
Formulary
|
NICE TA974: Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma |
| Selinexor |
08.01.05 |
Formulary
|
NICE TA970: Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments |
| Selpercatinib |
08.01.05 |
Formulary
|
NICE TA1039: Selpercatinib for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over |
| Selpercatinib |
08.01.05 |
Formulary
|
NICE TA1042: Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer |
| Selpercatinib |
08.01.05 |
Formulary
|
NICE TA1038: Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and over |
| Selpercatinib |
08.01.05 |
Formulary
|
NICE TA911: Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer |
| Selpercatinib |
08.01.05 |
Formulary
|
NICE TA1042: Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer |
| Selumetinib |
08.01.05 |
Formulary
|
NICE HST20 Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over |
| Selumetinib |
08.01.05 |
Formulary
|
NICE HST20: Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over |
| Semaglutide |
06.01.02.03 |
Formulary
|
NICE TA875: Semaglutide for managing overweight and obesity |
| Semaglutide |
06.01.02.03 |
Formulary
|
NICE TA875: Semaglutide for managing overweight and obesity |
| Setmelanotide |
06.07 |
Formulary
|
NICE HST21: Setmelanotide for treating obesity caused by LEPR or POMC deficiency |
| Setmelanotide |
06.07 |
Formulary
|
NICE HST31: Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome |
| Simeprevir |
05.03.03.02 |
Non Formulary
|
NICE TA331: Simeprevir with peginterferon alfa & ribavirin for hepatitis C |
| Siponimod |
08.02.04 |
Formulary
|
NICE TA656: Siponimod for treating secondary progressive multiple sclerosis |
| Sipuleucel- T |
20 |
Non Formulary
|
NICE TA322: Sipuleucel-T for prostate cancer |
| Smoking Cessation Therapy |
04.10.02 |
Formulary
|
NICE NG209: Tobacco: preventing uptake, promoting quitting and treating dependence |
| Smoking Cessation Therapy |
04.10.02 |
Formulary
|
NICE TA123: Varenicline for smoking cessation |
| Sodium thiosulfate (anhydrous) |
08.01 |
Formulary
|
NICE TA1034: Anhydrous sodium thiosulfate for preventing hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years with localised solid tumours |
| Sodium zirconium cyclosilicate |
09.02.01.01 |
Formulary
|
NICE TA599: Sodium zirconium cyclosilicate for treating hyperkalaemia |
| Sofosbuvir |
05.03.03.02 |
Formulary
|
NICE TA330: Sofosbuvir for treating chronic hepatitis C |
| Sofosbuvir & Ledipasvir |
05.03.03.02 |
Formulary
|
NICE TAG63: Ledipasvir–sofosbuvir for treating chronic hepatitis C |
| Sofosbuvir & velpatasvir |
05.03.03.02 |
Formulary
|
NICE TA430: Sofosbuvir–velpatasvir for treating chronic hepatitis C |
| Sofosbuvir, Velpatasvir & Voxilaprevir |
05.03.03.02 |
Formulary
|
NICE TA507: Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C |
| Solriamfetol |
04.04 |
Formulary
|
NICE TA758: Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy |
| Solriamfetol |
04.04 |
Formulary
|
NICE TA777: Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea (Not Recommended) |
| Somapacitan |
06.05.01 |
Formulary
|
NICE TA1066: Somapacitan for treating growth hormone deficiency in people 3 to 17 years |
| Somatrogon |
06.05.01 |
Formulary
|
NICE TA863: Somatrogon for treating growth disturbance in children and young people aged 3 years and over |
| Somatropin - adults |
06.05.01 |
Formulary
|
NICE TA64: Human growth hormone (somatropin) in adults with growth hormone deficiency |
| Somatropin (children) |
06.05.01 |
Formulary
|
NICE TA188: Human growth hormone (somatropin) for the treatment of growth failure in children |
| Sorafenib |
08.01.05 |
Formulary
|
NICE TA474 Sorafenib for treating advanced hepatocellular carcinoma |
| Sorafenib |
08.01.05 |
Formulary
|
NICE TA 535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine |
| Sotagliflozin |
06.01.02.03 |
Formulary
|
NICE TA622: Sotagliflozin with insulin for treating type 1 diabetes |
| Sotorasib |
08.01.05 |
Formulary
|
NICE TA781: Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer |
| Sotrovimab |
05.03.06 |
Formulary
|
NICE TA878: Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 |
| Sparsentan |
02.05.05 |
Formulary
|
NICE TA1074: Sparsentan for treating primary IgA nephropathy |
| Spesolimab |
13.05.03 |
Formulary
|
NICE TA1070: Spesolimab for treating generalised pustular psoriasis flares |
| Sunitinib |
08.01.05 |
Formulary
|
NICE TA449 Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease |
| Sunitinib |
08.01.05 |
Formulary
|
NICE TA169: Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma |
| Sunitinib |
08.01.05 |
Formulary
|
NICE TA179: Sunitinib for the treatment of gastrointestinal stromal tumours |
| Tacrolimus |
08.02.02 |
Formulary
|
NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people |
| Tacrolimus |
08.02.02 |
Formulary
|
NICE TA481: Immunosuppressive therapy for kidney transplant in adults |
| Tacrolimus ointment |
13.05.03 |
Formulary
|
NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema) |
| Tafamidis |
04.12 |
Formulary
|
NICE TA984: Tafamidis for treating transthyretin amyloidosis with cardiomyopathy |
| Tafasitamab |
08.01.05 |
Non Formulary
|
NICE TA883: Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma |
| Talazoparib |
08.01.05 |
Formulary
|
NICE TA952: Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations |
| Talimogene laherparepvec |
08.01.05 |
Formulary
|
NICE TA410: Talimogene laherparepvec for treating unresectable metastatic melanoma |
| Tarlatamab |
08.01.05 |
Non Formulary
|
NICE TA883: Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma |
| Tarlatamab |
08.01.05 |
Non Formulary
|
NICE TA883: Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma |
| Tebentafusp |
08.01.05 |
Formulary
|
NICE TA1027:Tebentafusp for treating advanced uveal melanoma |
| Teclistamab |
08.01.05 |
Formulary
|
NICE TA1015: Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments |
| Teduglutide |
01.04.02 |
Formulary
|
NICE TA804: Teduglutide for treating short bowel syndrome |
| Tegafur with Uracil |
08.01.03 |
Formulary
|
NICE TA61: Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer |
| Telaprevir |
05.03.03.02 |
Non Formulary
|
NICE TA252: Telaprevir in hepatitis C |
| Temozolomide |
08.01.05 |
Formulary
|
NICE TA23: Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer) |
| Temozolomide |
08.01.05 |
Formulary
|
NICE TA121: Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma |
| Tenecteplase |
02.10.02 |
Formulary
|
NICE TA990: Tenecteplase for treating acute ischaemic stroke |
| Tenofovir Disproxil |
05.03.03.01 |
Formulary
|
NICE TA173: Hepatitis B (chronic) - tenofovir disoproxil |
| Tenofovir Disproxil |
05.03.03.01 |
Formulary
|
NICE CG165: Hepatitis B (incorporates TA153) |
| Tepotinib |
08.02 |
Formulary
|
NICE TA789: Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations |
| Teriflunomide |
08.02.04 |
Formulary
|
NICE TA303: Teriflunomide for treating relapsing–remitting multiple sclerosis |
| Teriparatide 250microgram in 1ml prefilled pen |
06.06.01 |
Formulary
|
NICE TA160: Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women |
| Teriparatide 250microgram in 1ml prefilled pen |
06.06.01 |
Formulary
|
NICE TA161: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women |
| Teriparatide 250microgram in 1ml prefilled pen |
06.06.01 |
Formulary
|
NICE TA161: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women |
| Teriparatide 250microgram in 1ml prefilled pen |
06.06.01 |
Formulary
|
NICE TA160: Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women |
| Testosterone Gel |
06.04.02 |
Formulary
|
NICE NG23: Menopause: diagnosis and management |
| Tezacaftor and ivacaftor |
03.07 |
Formulary
|
TA988: Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis |
| Tezacaftor with ivacaftor and elexacaftor |
03.07 |
Formulary
|
TA988: Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis |
| Tezacaftor with vanzacaftor and deutivacaftor |
03.07 |
Formulary
|
NICE TA1085: Vanzacaftor-tezacaftor-deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over |
| Tezepelumab |
03.04.02 |
Formulary
|
NICE TA880: Tezepelumab for treating severe asthma |
| Thalidomide |
08.02.04 |
Formulary
|
NICE TA228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma |
| Thiamine |
09.06.02 |
Formulary
|
NICE CG100: Management of alcohol-related physical complications |
| Thiamine |
09.06.02 |
Formulary
|
NICE CG115: Alcohol dependence - diagnosis, assessment and management |
| Thiamine Injection |
09.06.02 |
Formulary
|
NICE CG115: Alcohol dependence - diagnosis, assessment and management |
| Thiamine Injection |
09.06.02 |
Formulary
|
NICE CG100: Management of alcohol-related physical complications |
| Ticagrelor |
02.09 |
Formulary
|
NICE TA236: Ticagrelor for the treatment of acute coronary syndromes |
| Ticagrelor |
02.09 |
Formulary
|
NICE TA420: Ticagrelor for preventing atherothrombotic events after myocardial infarction |
| Tildrakizumab |
13.05.03 |
Formulary
|
NICE TA575: Tildrakizumab for treating moderate to severe plaque psoriasis |
| Tirzepatide |
06.01.02.03 |
Formulary
|
NICE TA924: Tirzepatide for treating type 2 diabetes |
| Tirzepatide |
06.01.02.03 |
Formulary
|
NICE TA1026: Tirzepatide for managing overweight and obesity |
| Tisagenlecleucel |
08.01.05 |
Non Formulary
|
NICE TA933: Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (terminated appraisal) |
| Tisagenlecleucel |
08.01.05 |
Formulary
|
NICE TA975: Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under |
| Tivozanib |
08.01.05 |
Formulary
|
NICE TA512: Tivozanib for treating advanced renal cell carcinoma |
| Tixagevimab plus cilgavimab |
05.03.06 |
Non Formulary
|
NICE TA971: Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 |
| Tobramycin |
05.01.04 |
Formulary
|
TA276:Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis |
| Tobramycin inhaler |
05.01.04 |
Non Formulary
|
NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin |
| Tocilizumab |
10.01.03 |
Formulary
|
NICE TA247: Tocilizumab for the treatment of rheumatoid arthritis |
| Tocilizumab |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Tocilizumab |
10.01.03 |
Formulary
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis |
| Tocilizumab |
10.01.03 |
Formulary
|
NICE TA518: Tocilizumab for treating giant cell arteritis |
| Tofacitinib |
10.01.03 |
Formulary
|
NICE TA547: Tofacitinib for moderately to severely active ulcerative colitis |
| Tofacitinib |
10.01.03 |
Formulary
|
NICE TA543: Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs |
| Tofacitinib |
10.01.03 |
Formulary
|
NICE TA480: Tofacitinib for moderate to severe rheumatoid arthritis Technology appraisal guidance |
| Tofacitinib |
10.01.03 |
Formulary
|
NICE TA735: Tofacitinib for treating juvenile idiopathic arthritis |
| Tofacitinib |
10.01.03 |
Formulary
|
NICE TA920: Tofacitinib for treating active ankylosing spondylitis |
| Tofacitinib |
01.05.03 |
Formulary
|
NICE TA547: Tofacitinib for moderately to severely active ulcerative colitis |
| Tolvaptan |
06.05.02 |
Formulary
|
NICE TA358: Autosomal dominant polycystic kidney disease - tolvaptan |
| Tolvaptan |
06.05.02 |
Non Formulary
|
NICE TA358: Autosomal dominant polycystic kidney disease - tolvaptan |
| Topotecan |
08.01.05 |
Formulary
|
NICE TA183: Topotecan for the treatment of recurrent and stage IVB cervical cancer |
| Topotecan |
08.01.05 |
Formulary
|
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
| Topotecan |
08.01.05 |
Formulary
|
NICE TA184: Topotecan for the treatment of relapsed small-cell lung cancer |
| Trabectedin |
08.01.05 |
Formulary
|
NICE TA185: Soft tissue sarcoma - trabectedin |
| Trabectedin |
08.01.05 |
Formulary
|
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
| Tralokinumab |
13.05.03 |
Formulary
|
NICE TA814: Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis |
| Trametinib |
08.01.05 |
Formulary
|
NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma |
| Trametinib |
08.01.05 |
Formulary
|
NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma |
| Trametinib |
08.01.05 |
Formulary
|
NICE TA898: Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer |
| Trametinib |
08.01.05 |
Formulary
|
NICE TA977: Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over |
| Trastuzumab |
08.01.05 |
Formulary
|
NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer |
| Trastuzumab |
08.01.05 |
Formulary
|
NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab |
| Trastuzumab |
08.01.05 |
Formulary
|
NICE TA34: Breast cancer - trastuzumab |
| Trastuzumab |
08.01.05 |
Formulary
|
NICE NG101: Early and locally advanced breast cancer: diagnosis and management |
| Trastuzumab deruxtecan |
08.01.05 |
Formulary
|
NICE TA862: HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments |
| Trastuzumab deruxtecan |
08.01.05 |
Formulary
|
NICE TA704: Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies |
| Trastuzumab deruxtecan |
08.01.05 |
Non Formulary
|
NICE TA976: Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) |
| Trastuzumab deruxtecan |
08.01.05 |
Non Formulary
|
TA992: Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy |
| Trastuzumab emtansine |
08.01.05 |
Formulary
|
NICE TA458 Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane |
| Trastuzumab emtansine |
08.01.05 |
Formulary
|
NICE TA632: Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer |
| Treosulfan |
08.01.01 |
Formulary
|
NICE TA640: Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant |
| Treosulfan |
08.01.01 |
Non Formulary
|
NICE TA945: Treosulfan with fludarabine before allogeneic stem cell transplant for people aged 1 month to 17 years with non-malignant diseases (terminated appraisal) |
| Trifluridine and tipiracil |
08.01.03 |
Formulary
|
NICE TA 405 - Trifluridine–tipiracil for previously treated metastatic colorectal cancer |
| Trifluridine and tipiracil |
08.01.03 |
Formulary
|
NICE TA852: Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatments |
| Trifluridine and tipiracil |
08.01.03 |
Formulary
|
NICE TA1008 : Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments |
| Tucatinib |
08.01.05 |
Formulary
|
NICE TA786: Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies |
| Ublituximab |
08.02.03 |
Formulary
|
NICE TA1025: Ublituximab for treating relapsing multiple sclerosis |
| Upadacitinib |
13.05.03 |
Formulary
|
NICE TA814: Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis |
| Upadacitinib |
01.05.03 |
Formulary
|
NICE TA905: Upadacitinib for previously treated moderately to severely active Crohn’s disease |
| Upadacitinib |
01.05.03 |
Formulary
|
NICE TA856: Upadacitinib for treating moderately to severely active ulcerative colitis |
| Upadacitinib |
10.01.03 |
Formulary
|
NICE TA768: Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs |
| Upadacitinib |
10.01.03 |
Formulary
|
NICE TA814: Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis |
| Upadacitinib |
10.01.03 |
Formulary
|
NICE TA744: Upadacitinib for treating moderate rheumatoid arthritis |
| Upadacitinib |
10.01.03 |
Formulary
|
NICE TA861: Upadacitinib for treating active non-radiographic axial spondyloarthritis |
| Upadacitinib |
10.01.03 |
Formulary
|
NICE TA665: Upadacitinib for treating severe rheumatoid arthritis |
| Upadacitinib |
10.01.03 |
Formulary
|
NICE TA829: Upadacitinib for treating active ankylosing spondylitis |
| Ustekinumab |
01.05.03 |
Formulary
|
NICE TA456 Ustekinumab for moderately to severely active Crohn’s disease after previous treatment |
| Ustekinumab |
01.05.03 |
Formulary
|
NICE TA633: Ustekinumab for treating moderately to severely active ulcerative colitis |
| Ustekinumab |
10.01.03 |
Formulary
|
NICE TA340: Ustekinumab for treating active psoriatic arthritis (Updated March 2017) |
| Ustekinumab |
13.05.03 |
Formulary
|
NICE TA180: Psoriasis - ustekinumab (Updated March 2017) |
| Ustekinumab |
13.05.03 |
Formulary
|
NICE TA455 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
| Vadadustat |
09.01.03 |
Formulary
|
NICE TA1035: Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease |
| Vaginal Devices |
07.04.02 |
Formulary
|
NICE NG210: Pelvic floor dysfunction: prevention and non-surgical management |
| Vamorolone |
10.02 |
Formulary
|
NICE TA1031:Vamorolone for treating Duchenne muscular dystrophy in people 4 years and over |
| Varenicline |
04.10.02 |
Formulary
|
NICE TA123: Varenicline |
| Vedolizumab |
01.05.03 |
Formulary
|
NICE TA826: Vedolizumab for treating chronic refractory pouchitis after surgery for ulcerative colitis (terminated appraisal) |
| Vedolizumab |
01.05.03 |
Formulary
|
NICE TA352: Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy |
| Vedolizumab |
01.05.03 |
Formulary
|
NICE TA342: Vedolizumab for treating moderately to severely active ulcerative colitis |
| Velmanase alfa |
09.08.01 |
Formulary
|
NICE HST29: Velmanase alfa for treating alpha-mannosidosis |
| Vemurafenib |
08.01.05 |
Formulary
|
NICE TA269: Vemurafenib for treating malignant melanoma |
| Vemurafenib |
08.01.05 |
Formulary
|
NICE TA414: Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma |
| Venetoclax |
08.01.05 |
Formulary
|
NICE TA663 Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia |
| Venetoclax |
08.01.05 |
Formulary
|
NICE TA765: Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable |
| Venetoclax |
08.01.05 |
Formulary
|
NICE TA787: Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable |
| Venetoclax |
08.01.05 |
Formulary
|
NICE TA796: Venetoclax for treating chronic lymphocytic leukaemia |
| Venetoclax |
08.01.05 |
Formulary
|
NICE TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia |
| Verteporfin 15mg Injection |
11.08.02 |
Formulary
|
NICE NG82: Age-related macular degeneration |
| Vibegron |
07.04.02 |
Formulary
|
NICE TA999: Vibegron for treating symptoms of overactive bladder syndrome |
| Vinflunine |
08.01.04 |
Non Formulary
|
NICE TA272: Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine |
| Vitamin B & C injection |
09.06.02 |
Formulary
|
NICE CG115: Alcohol dependence - diagnosis, assessment and management |
| Vitamin B & C injection |
09.06.02 |
Formulary
|
NICE CG100: Management of alcohol-related physical complications |
| Voclosporin |
08.02.02 |
Formulary
|
NICE TA882: Voclosporin with mycophenolate mofetil for treating lupus nephritis |
| Volanesorsen |
19 |
Formulary
|
NICE HST 13: Volanesorsen for treating familial chylomicronaemia syndrome |
| Voretigene neparvovec |
11.08.02 |
Formulary
|
NICE HST11: Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations |
| Vortioxetine |
04.03.04 |
Formulary
|
NICE TA367: Vortioxetine for treating major depressive episodes |
| Vortioxetine |
04.03.03 |
Non Formulary
|
NICE TA367 - Vortioxetine for treating major depressive episodes |
| Vutrisiran |
04.12 |
Formulary
|
NICE TA868: Vutrisiran for treating hereditary transthyretin-related amyloidosis |
| White birch (Betula verrucosa) 12 SQ-Bet |
03.04.02 |
Formulary
|
NICE TA1087: Betula verrucosa for treating moderate to severe allergic rhinitis or conjunctivitis caused by tree pollen |
| Zanabrutinib |
08.01.05 |
Formulary
|
NICE TA931: Zanubrutinib for treating chronic lymphocytic leukaemia |
| Zanamivir |
05.03.04 |
Formulary
|
NICE TA168: Amantadine, oseltamivir and zanamivir for the treatment of influenza |
| Zanamivir |
05.03.04 |
Formulary
|
NICE TA158: Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza |
| Zanamivir Injection |
05.03.04 |
Formulary
|
NICE TA168: Amantadine, oseltamivir and zanamivir for the treatment of influenza |
| Zanamivir Injection |
05.03.04 |
Formulary
|
NICE TA158: Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza |
| Zanubrutinib |
08.01.05 |
Formulary
|
NICE TA833: Zanubrutinib for treating Waldenstrom’s macroglobulinaemia |
| Zanubrutinib |
08.01.05 |
Formulary
|
NICE TA1081: Zanubrutinib for treating relapsed or refractory mantle cell lymphoma |
| Zanubrutinib |
08.01.05 |
Formulary
|
NICE TA1001 : Zanubrutinib for treating marginal zone lymphoma after anti-CD20-based treatment |
| Zanubrutinib |
08.01.05 |
Formulary
|
NICE TA931: Zanubrutinib for treating chronic lymphocytic leukaemia |
| Zanubrutinib |
08.01.05 |
Non Formulary
|
NICE TA978: Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments (terminated appraisal) |
| zolbetuximab |
08.01.05 |
Non Formulary
|
NICE TA1046: Zolbetuximab with chemotherapy for untreated claudin-18.2-positive HER2-negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma |
| Zoledronic Acid 5mg injection |
06.06.02 |
Formulary
|
NICE TA464 Bisphosphonates for treating osteoporosis |
| Zolpidem |
04.01.01 |
Formulary
|
NICE TA77: Zaleplon, zolpidem and zopiclone for the management of insomnia |
| Zopiclone |
04.01.01 |
Formulary
|
NICE TA77: Zaleplon, zolpidem and zopiclone for the management of insomnia |
